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ABSTRACT 
Background: A common feature of most reviews or catalogues of health utilities has been their 
focus on adult health states or derivation of values from adult populations. More generally, 
utility measurement in or on behalf of children has been constrained by a number of 
methodological concerns. The objective of this study was to conduct the first comprehensive 
systematic review and meta-analysis of primary utility data for childhood conditions and 
descriptors and to determine the effects of methodological factors on childhood utilities. 
Methods: The review followed PRISMA guidelines. PubMed, Embase, Web of Science, 
PsycINFO, EconLit, CINAHL and Cochrane Library were searched for primary studies 
reporting health utilities for childhood conditions or descriptors using direct or indirect 
valuation methods. The Pediatric Economic Database Evaluation (PEDE) was also searched 
for cost-utility analyses with primary utility values. Mean or median utilities for each of the 
main samples were catalogued, whilst weighted averages of utilities for each health condition 
were estimated, by valuation method. Mixed-effects meta-regression using hierarchical linear 
modelling was conducted for the most common valuation methods to estimate the utility 
decrement for each health condition category relative to general childhood population health, 
as well as the independent effects of methodological factors.  
Results: The literature searches resulted in 272 eligible studies. These yielded 3,414 utilities 
when all sub-groups were considered, covering all ICD-10 chapters relevant to childhood 
health, 19 valuation methods, 12 respondent types, 8 modes of administration, and data from 
36 countries. A total of 1,191 utility values were obtained when only main study samples were 
considered and these were catalogued by health condition or descriptor, and methodological 
characteristics. 1,073 mean utilities for main samples were used for fixed-effects meta-analysis 
by health condition and valuation method. Mixed-effects meta-regressions estimated that 53 of 
76 ICD-10 delineated health conditions valued using the HUI3 were associated with 
statistically significant utility decrements relative to general population health, whilst 38 of 57 
valued using a Visual Analogue Scale (VAS) were associated with statistically significant VAS 
decrements. For both methods, parental proxy-assessment was associated with overestimation 
of values, whilst adolescents reported lower values than children under 12 years. VAS 
responses were more heavily influenced by mode of administration than the HUI3.  
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Conclusion: Utilities and their associated distributions, as well as the independent 
contributions of methodological factors, revealed by this systematic review and meta-analysis 
can inform future economic evaluations within the childhood context.  
Keywords: Systematic review; Meta-analysis; Meta-regression; PRISMA; Hierarchical linear 
model; Childhood health states; Health utility; Pediatric Economic Database Evaluation; 
Economic evaluation. 
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INTRODUCTION 
Economic evaluation involves the comparative analysis of alternative programmes or 
interventions in terms of their costs and consequences.1 It has increasingly been used to inform 
health care decision-making in the United Kingdom by bodies such as the National Institute 
for Health and Clinical Excellence (NICE) in England and Wales and the Scottish Medicines 
Consortium (SMC) for Scotland.2,3 Similarly, economic evaluation has increasingly been used 
to inform the health care decision-making processes of government agencies in other nations.4,5 
The preferred measure of health outcome for many government agencies tasked with setting 
health priorities under conditions of finite resources remains the quality-adjusted life year 
(QALY), a preference-based measure of health outcome that combines length of life and 
health-related quality of life (HRQoL) in a single metric.6 For government agencies, the QALY 
has the advantage of allowing cost-effectiveness comparisons to be made across different 
health care interventions for disparate health conditions. For economists, it offers an additional 
advantage in that the techniques used to derive the QALY reflect, to varying degrees, people’s 
preferences for health outcomes, thereby moving beyond the narrow biomedical model towards 
an extra-welfarist approach that informs allocative decision-making.1  
     Health economists have developed a number of approaches for estimating preference-based 
HRQoL weights (or health utilities) associated with different health conditions (or health 
states) for inclusion within the QALY metric.7 These include scaling techniques, such as the 
Standard Gamble (SG) and Time Trade-Off (TTO) approaches;8 health rating scales, such as 
the Visual Analogue Scale (VAS); multi-attribute health status classification systems with 
preference scores, such as the EQ-5D,9 Health Utilities Index (HUI),10 SF-6D,11 Quality of 
Well-Being Scale12 and Assessment of Quality of Life (AQoL or AQoL-5D);13 and mapping 
from non-preference-based measures onto generic preference-based measures of health.14 As 
measurement of preferences and valuation occur in a single step, the SG, TTO and VAS 
methods are commonly referred to as direct valuation methods. In contrast, multi-attribute 
health indices with preference scores make use of classification systems for measurement and 
apply a pre-existing valuation or tariff set. These are commonly referred to as indirect valuation 
methods. Both direct and indirect valuation methods have been widely applied within health 
economic evaluations.7 However, there are several circumstances, particularly in the context 
of decision-analytic modelling based economic evaluations, where analysts lack the time and 
resources to obtain original health utility data for all health conditions or states of interest. In 
such cases, methodological guidance documents generally recommend that analysts: (i) resort 
to published literature for health utilities; (ii) use approaches for identifying and synthesising 
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health utilities evidence in accordance with the general principles of evidence-based medicine; 
and (iii) use methods that are justifiable and reproducible.15 
     A number of structured or systematic reviews of health utility values have been reported in 
the literature, the results of which have acted as data inputs into economic evaluations. Tengs 
and Wallace16 identified 1,000 original health utility values in 154 studies. Bell and 
colleagues17 conducted a systematic review of cost-utility analyses published between 1976 
and 1997 and identified 949 health utility values in 228 studies. More recently, systematic 
reviews of health utilities have been reported for a number of specific clinical conditions, 
including but not limited to liver disease,18 neuropathic pain,19 Alzheimer’s disease,20 unipolar 
depression,21 colorectal cancer,22 HIV/AIDS,23 breast cancer,24 type II diabetes,25 surgical site 
infection,26 and Crohn’s disease and ulcerative colitis.27 
     A common feature of the vast majority of structured or systematic reviews of health utility 
values has been a focus on adult health conditions or states or derivation of values from adult 
populations. Reviews of health utility values for childhood health conditions or states have 
been limited to a small number of health conditions such as acute lymphoblastic leukaemia, 
asthma, cancer, diabetes and skin diseases.28,29 The recent review of health utilities in children 
and adolescents conducted by Thorrington and Eames30 was restricted to evidence from 90 
studies, and reports results by valuation method, country of origin and year of publication, 
rather than by health condition or state. Moreover, published catalogues of health utility values 
for childhood health conditions have been limited to a relatively small number of conditions 
valued using a single valuation method and a single source of values.31-33 Another source of 
childhood utility values is the Paediatric Economic Database Evaluation (PEDE) project, a 
searchable online repository of paediatric economic evaluations including 784 cost-utility 
analyses published between 1980 and 2015 from which 1,842 utility weights are available.34 
However, only 72 of these cost-utility analyses estimated primary utility values from childhood 
populations or their proxies; the remainder derived utility weights from the literature, adult 
studies, or expert opinion.35 This finding is consistent with an earlier review in 2012 by Kromm 
and colleagues36 of 213 cost-utility analyses in PEDE published between 1997 and 2009: they 
found that only 16 analyses measured utilities from children or their proxies, 134 relied on 
author assumption or adult and/or paediatric literature and 13 used expert opinion. Even when 
utility weights are derived from the literature, a concern is that published cost-utility analyses 
often provide very little description of relevant design features surrounding the derivation of 
utility values. Moreover, the utility weights contained in PEDE are restricted to those extracted 
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from published cost-utility analyses, thus representing only one source of childhood utilities 
measured by primary studies.  
     Faced therefore with a paucity of reliable primary utility data for childhood health states 
and associated descriptors, analysts conducting cost-effectiveness modelling studies in child 
health have commonly applied health utility values derived for adults to childhood health 
states.37 The concern is that analysts are overlooking a range of methodological concerns that 
are likely to reduce the suitability of adult-centred or adult-derived values for childhood health 
states. These include the relevant attributes to incorporate into measurement instruments, 
appropriate respondents for measurement exercises, potential sources of bias in the description 
and valuation processes, and the psychometric properties of existing measures.38 These 
limitations have been mitigated to a degree by the development of childhood- and adolescent-
specific multi-attribute health classification systems generating preference-based scores, such 
as the EQ-5D-Y (Youth),39 16-Dimensional Health-Related Measure (16D),40 17-Dimensional 
Health-Related Measure (17D),41 AQoL-6D42 and Child Health Utility 9-Dimensions 
(CHU9D),43 recently reviewed by Chen and Ratcliffe.44 Nevertheless, variation between 
measures in choice of attributes and their conceptual underpinnings, valuation protocol, choice 
of informant, appropriateness for each developmental stage, and formatting, is likely to 
independently impact on health utility values. To generate reliable results from paediatric cost-
utility analyses that can inform health care decision making, it is important that analyses apply 
valid health utility estimates after accounting for influences of these methodological factors. 
     In this paper, we report the results of the first comprehensive systematic review of health 
utility values for childhood conditions and broader descriptors. The paper also reports meta-
regressions that determine the effects of a range of methodological factors on these health 
utility values. It is anticipated that the results of this systematic review and meta-regressions 
will act as a significant new resource for analysts conducting paediatric cost-utility analyses. 
 
METHODS 
Systematic Review 
The systematic review followed the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines.45 A comprehensive literature search strategy was developed 
and piloted. The final search strategy applied an intersection of health utility, valuation method 
and childhood search terms, and is presented in full in the supplementary material. A separate 
search strategy that additionally applied ‘quality of life’ or ‘health-related quality of life’ search 
terms during piloting did not yield any additional relevant articles or reports (hereafter articles 
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for brevity), and was therefore not pursued. The following databases were searched: PubMed, 
Embase of OVID Medline, Web of Science, PsycINFO, Cochrane Library, CINAHL and 
EconLit. Searches of titles and abstract were applied to articles published online before 31st 
December 2015. Non-English language articles were excluded. A search of the PEDE database 
was also conducted to identify cost-utility analyses published between 1980 and 2015 reporting 
health utilities for childhood conditions or broader descriptors. 
     The main inclusion criteria for the search strategy were primary studies reporting health 
utilities for childhood populations or for childhood conditions or descriptors using direct or 
indirect valuation methods. Duplicates of identified articles were removed using EndNote 
version 7.7. Previous related literature reviews28-30,46-48 were excluded, but used for manual 
reference searching. Titles and abstracts were assessed at the first stage of the review by two 
independent reviewers (JK and SWK). If an article received two approvals, it proceeded to the 
next stage, with disagreements referred to a third reviewer (SP) for the final assessment. The 
same reviewers searched full-text articles at the second stage of the review with disagreements 
again referred to the third reviewer for final assessments. We excluded studies at the full article 
stage that were: (1) not published in the English language; (2) decision-analytic modelling 
based economic evaluations that relied purely on secondary data; (3) studies that reported only 
single-attribute scores for indirect utility instruments; or (4) studies where the main samples 
had a mean or median target age exceeding 18 years. Conference abstracts were included if 
they reported original health utility values. Similarly, studies reporting primary VAS scores 
were included despite disagreement amongst many health economists about their theoretical 
basis for QALY construction.49 
Data Extraction 
From each article that met the study selection criteria, we extracted the following information 
about the characteristics of the study using a bespoke proforma: (1) bibliographic details, 
including year of publication; (2) country/geographical jurisdiction; (3) setting (hospital 
inpatient ward, hospital outpatient clinic, general practice, school, via post, via internet, other); 
(4) health descriptor(s), which could take the form of a health condition/disease, health state or 
intervention descriptor; (5) respondent type (self-assessment by children, proxy-assessment by 
parents, caregivers, nurses, physicians, other proxies); (6) age of target childhood group 
(reported as age at diagnosis, age at study, and associated descriptive statistics); (7) size of 
study population; (8) direct valuation method applied (if applicable); (9) indirect valuation 
method applied (if applicable); (10) utility tariff if indirect valuation method applied; (11) 
utility or VAS scores (including central statistics and measures of variability); (12) study design 
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(cross-sectional study, clinical trial, prospective observational, internet survey, other); (13) 
response quality (response rate, information on dropouts, reasons for loss to follow-up, etc.); 
(14) statistical method for analysing utilities; and (15) any reported methodological concerns. 
A point was given to the reporting of each of these characteristics, and the total points were 
interpreted as the overall reporting quality score. All data were entered into an Excel database.  
     After completing the database, a subset including only data for the main study samples 
within each article was created. This subset excluded data for any potentially overlapping sub-
samples based on sociodemographic characteristics, for example, gender or age. If an article 
reported utility or VAS scores for a health condition or descriptor using two or more valuation 
methods or two or more respondent types, each set of utility values was treated as a separate 
main sample. For randomised controlled trials or prospective observational intervention 
studies, only pre-treatment values were treated as main samples. This was to reduce a further 
layer of confounding introduced by intervention effects. Finally, only samples reporting mean 
or median utility or VAS scores associated with an identifiable health condition or descriptor 
were included as main samples. This meant exclusion of samples reporting only mean change 
in utility or VAS score or regression coefficients.  
     An International Classification of Diseases 10th revision (ICD-10) code was allocated to 
each sample within the database. Where data permitted, health conditions were characterised 
by (i) ICD-10 chapter; (ii) ICD-10 sub-chapter encompassing a range of ICD-10 codes; and 
(iii) specific ICD-10 codes. Any health condition with three or more main study samples 
reporting mean utility or VAS scores (i.e. excluding median utility or VAS scores) was treated 
as a unique health condition category within an ICD-10 chapter. If a health condition contained 
two or less main study samples, it was grouped with other health conditions at the more 
aggregate level of the ICD-10 sub-chapter. The categorisation of childhood health states was 
subsumed into the above process.  
Statistical Analysis 
Two broad statistical analysis approaches were followed. For both approaches, only the main 
samples reporting mean utility or VAS scores were used (for completeness descriptive statistics 
for sub-samples are reported in the online Excel database at 
http://childhoodutilities.wordpress.com). The first approach estimated weighted averages of 
mean utility or VAS scores for each health condition category, by valuation method (a fixed-
effects meta-analysis). Each mean utility or VAS score was weighted by the inverse of its 
sample variance, defined as the square of the standard error of the sample mean.50  
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     The second analytical approach used a hierarchical linear model (HLM) in a linear mixed-
effects meta-regression.22-24 The aim was to estimate the utility or VAS score decrement of 
each health condition category relative to general population health, after controlling for 
methodological factors and study-specific random effects not accounted for by the explanatory 
variables. HLM introduces three levels of random variation. First, the variation of the observed 
mean utility or VAS score around the true mean value; second, the within-study variation in 
true mean value after controlling for explanatory variables; and, third, the between-study 
variation in true mean utility or VAS score after controlling for explanatory variables. Hence, 
the model allows for both within-study clustering and between-study variation in utility or VAS 
score.23 Analyses were restricted to main samples using the two most common valuation 
methods within the dataset, namely the Health Utilities Index Mark 3 (HUI3) and VAS variants 
(including standard VAS, EQ-5D VAS and EQ-5D-Y VAS). The rationale is that we expected 
valuation method to exert an independent effect on utility or VAS score, and that this effect 
might vary across health conditions.51 Hence, each analysis was restricted to samples covering 
all health conditions, but using a single valuation method. Mean utility or VAS scores were 
weighted by the inverse of their standard error, whilst individual studies were weighted by the 
total number of their respondents. Health condition categories, respondent types and modes of 
administration entered both HUI3 and VAS models as indicator variables. Both models also 
included a dummy variable for samples valuing hypothetical health states, a dummy variable 
for samples with minimum age greater than 12 years, and a dummy variable for samples from 
developing countries. All statistical analyses were conducted using STATA software, version 
14 (Stata-Corp, College Station, Texas, USA).  
 
RESULTS 
Systematic Review 
Figure 1 illustrates the flow of the systematic review process. The literature search resulted in 
27,119 individual articles. The first stage review of titles and abstracts excluded 26,634 articles. 
The main reasons for exclusion were targeting of non-childhood populations and use of non-
preference-based health outcome measures. Before the second stage review of full articles, 40 
articles (mostly conference abstracts) could not be accessed online. Of the 485 articles that 
progressed to the second stage, 214 were included in the final sample for data extraction. This 
sample included 14 conference abstracts. Manual reference searching based on these 214 
articles and previous systematic reviews28-30,46-48 yielded 43 further articles, whilst a search of 
the PEDE database yielded a further 15 articles. Thus, data was extracted from 272 primary 
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studies of health utilities for childhood conditions or descriptors. Appendix A summarises each 
of the 272 studies included in the systematic review by health condition, healthcare intervention 
where relevant, country of origin, country of tariff population, valuation method, respondent 
type, mode of administration, and age of target population. Appendix B provides the full 
references for each of these studies. The Excel database at 
http://childhoodutilities.wordpress.com summarises the characteristics of these studies with 
explanatory notes for navigation. 
Health Conditions by ICD-10 Chapter 
Table 1 summarises the results of the systematic review by ICD-10 chapters and health 
condition categories. Numbers of samples in each category are provided in the final column, 
whilst numbers of main samples reporting mean utility or VAS scores are provided in the 
parentheses in the same column. Health conditions with two or less main samples were grouped 
with other conditions within the same ICD-10 sub-chapter. For example, sickle cell disease 
(ICD-10 code 3-D57), favism (3-D55) and thalassemia (3-D56) were grouped in category 3.2 
representing ICD-10 sub-chapter for haemolytic anaemias (3-D55-D59) since each contained 
two or less main samples reporting mean values, and they were all characterised by the same 
ICD-10 sub-chapter. When conditions with two or less main samples were grouped together 
despite having ICD-10 codes that crossed ICD-10 sub-chapters, the resulting category was 
classified as “other type”, as in categories 2.12, 4.8, 5.8, 7.2, 11.4, 14.4, 17.3 and 19.3. 
Exceptions to these grouping rules were categories 1.8, 1.9, 2.6, 3.3, 11.2, 11.3, 12.2, 12.3, 
16.4, 21.2 and 21.3, where these conditions were deemed to be too dissimilar to be grouped 
together with another condition within the ICD-10 chapter. They are hence presented as unique 
categories despite having two or less main samples. Where health condition categories have 
been classified as “combined” (e.g. categories 2.1, 2.2, 19.1, 22), each sample contains patients 
of diverse health states. The Excel database should be referred to for information on each 
sample.  
     The largest number of samples are contained in category 0 representing general population 
health. This category contains samples of children and/or adolescents drawn from the general 
community or schools or control groups of healthy children within observational studies. 
Category 21 classifies samples by healthcare intervention rather than disease type. These 
samples are drawn from studies delineated by interventions or programmes and health 
condition is not specified.  
     Across all 101 health condition categories, there were 3,414 samples in total, 1,191 if only 
main samples reporting mean or median utility or VAS scores were considered, and 1,073 if 
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only main sample reporting mean values were considered. Inclusion of only mean values in the 
meta-regressions meant that some health condition categories were excluded, e.g., categories 
1.9 for chickenpox and 11.5 for celiac disease.  
     Disentangling potential intervention effects when selecting main samples was an imperfect 
process. For example, low birthweight or preterm children had often received paediatric 
intensive care, and hence main sample utility or VAS scores in categories 16.1, 16.2 and 16.3 
may have captured past intervention effects. Similarly, main sample utility or VAS scores in 
categories 9.3 and 14.1 may have captured the effects of organ transplants many years before 
the conduct of the observational studies.  
Study Characteristics 
Table 2 summarises the samples included in the analyses by valuation method, respondent type, 
mode of administration, minimum age of children in sample, and country of origin. The most 
commonly used direct valuation method was VAS (including standard VAS, EQ-5D VAS and 
EQ-5D-Y VAS), which was applied in 601 samples (247 main samples reporting mean or 
median utility or VAS scores). The most commonly used indirect valuation method was the 
HUI3.  
     Samples using the 15D, 16D or 17D were grouped together, even though each instrument 
is targeted at different age groups. One study used a 10-dimension variant of the HUI,52 whilst 
another assumed the value 0 indicated the worst imaginable health state rather than death for 
the HUI3.53 Samples from both studies were classified under a “Modified HUI” valuation 
method. The review included only one preference-based condition-specific instrument, the 
Pediatric Asthma Health Outcome Measure (PAHOM), developed by Chiou and colleagues.54 
Three studies mapped clinical measures for depression onto utility indices.55-57 Their samples 
were classified under the “Utility from non-preference-based measure (NPB)” category.  
      The respondent type with the largest number of main samples was proxy assessment by 
parents (n=408), followed by self-assessment by children and/or adolescents (n=349). In 151 
main samples, parents or caregivers valued the health states together with children. Types of 
proxy respondents varied widely, and included parents, caregivers, healthcare practitioners, the 
general public, and adult patients with the same disease.  
     Modes of administration were grouped under self-administration and interview-
administration. The most common mode of self-administration was non-postal survey (paper 
questionnaire) completed in a clinic or school. One study by Lee and colleagues58 used a Delphi 
survey of clinicians. Face-to-face interview was more widely used than any other mode of 
interview administration.  
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     Over one half of all samples (n=1,856) valued health states for children under 12 years. 
1,307 (70%) of these samples used a form of proxy-assessment. Similarly, 146 of 220 (66%) 
samples that contained infants (minimum age of 0) valued hypothetical health states using 
proxy-assessment. A significant number of samples (n=508) did not specify the target age.  
     The largest number of samples was surveyed in Canada, followed by the US and the UK.  
There were 3,153 samples from developed countries and just 255 from developing countries. 
Appendix A also specifies the country from which the utility tariff was derived when the study 
applied one or more indirect valuation method.  
Utility Catalogue 
Appendix C lists the main sample mean or median utility or VAS scores, and their associated 
distributions, for the 1,191 main samples by their ICD-10 chapter, health condition, valuation 
method, respondent type and sample size. Information on populations from which the indirect 
valuation methods’ tariffs were derived is provided at the bottom of the table. Appendix D 
provides the references for these tariffs. 
Weighted Average Values 
Table 3 outlines the results for the first part of the statistical analyses where weighted averages 
of main sample mean utility or VAS scores were calculated for each health condition category, 
by valuation method. Median utility or VAS scores were excluded from the analyses. The 
standard errors are reported in parentheses, whilst the ranges indicate the minimum and the 
maximum mean utility or VAS scores where applicable. The numbers of mean utility or VAS 
scores included in each analysis are presented in the second set of square brackets.  
Meta-Regressions 
Table 4 summarises the results of the meta-regression using HLM where only main samples 
that used the HUI3 were included, covering 279 samples across 89 studies and 76 health 
condition categories. The 0.876 constant represents the utility value for the baseline scenario, 
namely the weighted average of the mean HUI3 utility scores for general population samples, 
of minimum age less than 12 years from developed countries, with HRQoL self-assessed by 
children/adolescents using a self-administered survey in a health care or school setting. Health 
condition categories are included as indicator variables, and hence the coefficients for each 
condition category measures the decrement in mean HUI3 utility score from the baseline 
scenario. Using robust standard errors, 95% confidence intervals around the mean decrements 
can be calculated, as well as the associated p-values for statistical significance. For example, a 
utility decrement of 0.568 relative to baseline is provided for viral infections of the central 
nervous system (category 1.2), implying a mean utility score of 0.308 for this condition. The 
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health condition with the greatest utility decrement (excluding category 22 for combined 
chronic diseases) was category 21.3 for patients receiving palliative care (implied utility score 
of 0.017), followed by category 6.5 hydrocephalus (0.247) and category 17.4 congenital 
malformations of the nervous system (0.254). All categories containing cancer survivors 
(categories 2.1, 2.3, 2.7, 2.9, 2.10, 2.11 and 2.12) were associated with statistically significant 
utility increments relative to baseline, with the exception of brain tumour survivors (category 
2.5), which showed a statistically significant HUI3 decrement of 0.074 (P<0.001). Survivors 
of successful kidney transplant (category 14.1) were also associated with a statistically 
significant HRQoL improvement relative to baseline (HUI3 utility score increment of 0.111; 
P=0.016). Laryngotracheal stenosis (category 10.3) and congenital diaphragmatic hernia 
(category 11.2) were the only other conditions which were associated with a statistically 
significant HUI3 increment. Overall, at the 5% significance level, 53 of 76 ICD-10 delineated 
health conditions were associated with statistically significant HUI3 decrements. 
     The meta-regression also suggests that different respondent types exerted significant effects 
(where a utility score difference of 0.03 is deemed to be clinically significant)59 on health 
utility. Allowing children and/or adolescents to report their HRQoL together with their parents 
or caregivers led to an average decrement of 0.055 (P<0.001) in HUI3 score relative to when 
they report alone. Use of caregivers as proxies similarly led to an average decrement in utility 
score of 0.053 (P<0.001). In contrast, use of parents as proxies led to an overestimation of 
utility score (increment of 0.041; P=0.001) in comparison to the referent. Different modes of 
administration did not appear to exert statically significant effects on utility score relative to 
self-administration in a health care or school setting, except for telephone interview which 
resulted in a statically significant increment of 0.151 (P<0.001). Samples with a minimum age 
greater than 12 years (a proxy measure for adolescence) were associated with a statistically 
significant HUI3 decrement of 0.060 (P=0.033). Finally, children from developing countries 
reported a HUI3 decrement of 0.057, ceteris paribus, which was not statistically significant 
(P=0.219) despite the worse disease burden and healthcare environments they may face.  
     Table 5 summarises the meta-regression using HLM focussed on VAS-based approaches, 
covering 211 main samples across 67 studies and 57 health condition categories. The baseline 
scenario was associated with a VAS score of 82.88. As in Table 4, cancer survivorship 
(category 2.7) was associated with a better HRQoL than the baseline scenario (mean VAS 
increment of 12.58; P<0.001). Inflammatory and non-inflammatory disorders of the female 
pelvic organs (category 14.3) was the only other category associated with a significantly higher 
VAS score (mean increment of 7.52; P=0.021). Influenza and pneumonia (category 10.2), other 
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musculoskeletal disorders (13.4), imperforate anus (17.5) and survivors of other types of 
injuries (19.3) were associated with VAS increments which were not statistically significant at 
the 5% significance level. All other categories were associated with VAS decrements relative 
to the baseline scenario. At the 5% significance level, 38 of 57 ICD-10 delineated health 
conditions were associated with statistically significant VAS decrements.  
     Unlike the meta-regression for the HUI3, valuation of hypothetical health states was 
associated with a significant decrement in VAS score of 20.51 (P<0.001). Moreover, 
respondent type and mode of administration also exerted different influences on health 
outcome relative to the HUI3-based analysis. Assessment by children/adolescents together 
with parents or caregivers, and proxy-assessment by caregivers, were no longer associated with 
statistically significant underestimation of HRQoL. However, proxy-assessment by parents led 
to a statistically significant overestimation of HRQoL (VAS increment of 7.43; P=0.005), 
which was similar in relative magnitude and statistical significance to that revealed by the 
HUI3 analysis. Unlike for the HUI3, proxy-assessment by physicians or by the composite 
grouping of the general public, parents within the general public or adult patients resulted in a 
significant overestimation of the VAS score (for physicians: increment of 13.17; P<0.001; for 
composite group: 7.02; P=0.008). Furthermore, unlike for the HUI3, self-administered postal 
surveys were associated with an overestimation of VAS score relative to self-administration in 
health or school settings (increment of 4.63; P=0.058). Similarly, face-to-face interviews were 
associated with an overestimation of VAS score (increment of 5.99; P=0.011). As with the 
HUI3-based analyses, adolescents reported poorer HRQoL (VAS decrement of 5.45; P=0.026) 
relative to children under the age of 12. Similarly, children from developing countries reported 
poorer HRQoL (VAS decrement of 0.49), ceteris paribus, but this decrement was again not 
statistically significant.  
 
DISCUSSION 
This first comprehensive systematic review of primary studies reporting health utilities for 
childhood conditions and descriptors is substantially larger and broader in scope than previous 
reviews. It covers 272 studies as opposed to 90 studies by Thorrington and Eames30 and 77 
studies by Tarride and colleagues.29 Earlier systematic reviews concentrated on specific health 
conditions, such as acute lymphoblastic leukaemia,28,46 or on specific valuation methods, such 
as the EQ-5D.47 The study by Tarride and colleagues29 was also limited to four valuation 
methods (EQ-5D, HUI, SG and TTO) and four health conditions (asthma, cancer, diabetes, 
skin diseases). In contrast, this study covers 19 valuation methods and 99 health conditions, 
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grouped by ICD-10 codes. In comparison, Petrou and Kupek31 covered 43 health conditions 
described by 2,236 parents of disabled children in the UK and valued solely using the HUI3; 
Carroll and Downs32 covered 27 hypothetical health conditions valued by 4,016 parents from 
the general US public; and Mittmann and colleagues33 covered 19 health conditions 
experienced by 404 Canadian adolescents and valued solely using the HUI3. Moreover, this 
study is unique in detailing the characteristics of each of the included studies. The final 
catalogue of 1,191 mean or median utility or VAS scores corresponds in size to the largest 
published utility catalogues for adult populations, such as Tengs and Wallace’s16 catalogue of 
1,000 utility values. Furthermore, it is the only study that has applied a fixed-effects meta-
analysis and mixed-effects meta-regression to health utilities in childhood populations. The 
primary analytical approach, namely hierarchical linear modelling, has to date only been 
applied in adult populations and for specific health conditions, such as colorectal cancers,22 
HIV/AIDS23 and breast cancer.24 The studies by Tengs and Lin23 and Peasgood and 
colleagues24 similarly found that different respondent types exert independent effects on health 
utilities. These studies also share various limitations inherent in previous syntheses of utility 
values, such as unclear presentation of study characteristics (e.g. mode of administration) by 
primary sources,22 small data sets that restrict analyses of interaction effects between 
explanatory variables,23 the use of main study samples only that exclude some 
sociodemographic (e.g. gender) or clinical factors (e.g. symptom type and severity) as 
covariables,22,24 and the use of published material only.24 
     The finding from the meta-regression that 53 of 76 health condition categories were 
associated with statistically significant HUI3 decrements relative to general population health, 
after controlling for methodological factors, illustrates that this generic multi-attribute health 
classification instrument is sensitive to variations in health outcomes across a diverse range of 
disease areas in childhood health.60 The finding that long-term survivors of childhood cancer 
enjoy better health-related quality of life compared to cancer patients, and in some instances 
compared to children in the general population, is consistent with findings in primary case-
control studies (see for example Pogany and colleagues,61 and Apajasalo and colleagues62), and 
illustrates the importance of conducting health utility measurements to provide an evidence-
based justification for healthcare interventions in paediatric oncology.63,64 The VAS similarly 
seemed capable of detecting variations in health outcomes across conditions, associating 
survivorship of lymphoma (category 2.7) with a VAS increment relative to general population 
health and indicating a smaller VAS decrement for children born extremely preterm and 
without major comorbidity (category 16.1) than for those with major comorbidity (category 
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16.2), for example. It should be noted that the mixed effects meta-regression models test 
multiple hypotheses simultaneously, and caution is therefore required when drawing 
conclusions based on the P-values. Applying the Bonferroni correction to P-values would mean 
that only variables with P-values less than 0.00056 (0.05/89) for the HUI3 and 0.00071 
(0.05/70) for the VAS can be interpreted as reflecting significant effects.65 If a P-value less 
than 0.001 is adopted as the significance level, 50 out of 76 health condition categories for the 
HUI3 and 30 out of 57 for the VAS still exerted a significant impact on values relative to 
general population health. This suggests that the significant effects exerted by health conditions 
were not spurious results. 
     A number of methodological factors, including respondent type and mode of administration, 
were shown to have independent effects on both HUI3 and VAS scores after controlling for 
childhood health conditions. Of particular note was the finding that proxy assessment by 
parents is associated with an over-estimation of children’s HRQoL outcomes, compared to 
those reported directly by children for both methods, although a more mixed pattern of results 
was found when other types of proxies were considered. Previous studies had found that 
parental-assessed VAS scores are poorly correlated with those provided by children with 
chronic arthritis;66 that proxy-assessed HUI3 scores provided by caregivers are only moderately 
correlated with self-assessed scores provided by children with severe infections;67 and that 
proxy-assessed HUI3 scores provided by parents are significantly higher than those provided 
directly by very-low birthweight adolescents.68 A potential explanation for higher parental-
proxy values may be that parents underestimate problems in less observable aspects of health 
such as emotional and social wellbeing. which may be acute in childhood.68,69 Furthermore, 
previous evidence revealed variation in the reporting of children’s HRQoL outcomes by 
different types of proxies, for example, in the reporting of the HRQoL of young febrile children 
using a VAS by parents and physicians;70 the reporting of the HRQoL of children with acute 
lymphoblastic leukemia, juvenile idiopathic arthritis or asthma using the HUI3 by parents and 
physicians;71 and the assessment of the HRQOL of extremely-low birthweight adolescents 
using SG by neonatologists and parents.72    With respect to mode of administration, the meta-
regressions suggest that VAS measures of HRQoL outcomes were more significantly affected 
compared to the HUI3. These findings contradict those of Verrips and colleagues73 who found 
that telephone interviews underestimated HUI3 utility scores for very-low birthweight children 
relative to self-administered paper questionnaires in health or school settings.  Nevertheless, 
the results of meta-regressions should be seen as suggestive rather than definitive, and caution 
is required before interpreting them as accurate estimates of independent effects exerted by 
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various respondent types and modes of administration that can be generalised across all age 
groups and health conditions.  
     There are several caveats to the study results, which should be borne in mind by readers. 
First, our literature searches were limited to articles published online before 31st December 
2015. Nevertheless, we are not aware of any more recent evidence that would have a qualitative 
impact on our study results. Second, although our search strategies were extensively piloted to 
maximise sensitivity, some eligible articles may have been missed. Third, information on the 
samples included in our analyses was extracted from published material. Several studies did 
not report important data relating to population characteristics, such as comorbidities, which 
would have entered our meta-regressions had they been available. Fourth, our selection of 
valuation methods was broad and encompassed methods, such as VAS variants, which 
arguably lack a theoretical basis for inclusion within cost-utility analysis.49 Nevertheless, our 
approach is in keeping with previous systematic reviews of health utilities and permits the 
reader to select relevant values for their particular analysis.16,17 
     A more fundamental caveat relates to the assumptions that needed to be made to allow for 
evidence synthesis. Exploring the impact on utility scores across variations in methodological 
factors required making potentially inappropriate assumptions about the comparability of the 
diverse collection of studies included in the evidence base. Factors such as respondent type, 
administration mode and target age may differ substantially between studies, potentially 
undermining the credibility and relevance of utility estimates derived by pooling across them. 
This could potentially be exacerbated by our use of ICD-10 codes for categorising samples, if 
there are conditions that are qualitatively different, and have different associated utilities, but 
fall under the same ICD-10 code. Hierarchical linear modelling thus relaxes the strong 
assumptions around comparability implied by fixed-effects meta-analysis in two ways. The 
first is meta-regression, in which a regression model controlling for confounding factors is 
embedded in the meta-analysis. The second is random (or mixed) effects meta-analysis, which 
relaxes the assumption that studies in similar populations are reporting the same underlying 
utilities, and allows for heterogeneity between such studies from unobserved factors. However, 
mixed-effects meta-regression does not completely eliminate problems associated with the 
comparability of studies within the evidence base. There were limited data on which to base 
meta-regression (in particular, we were unable to estimate utilities conditional on disease 
severity). Issues associated with aggregation of health conditions using ICD-10 codes 
remained. Whilst most health condition categories were classified using distinct ICD-10 codes, 
paucity of data for some categories compelled aggregation within or across ICD-10 sub-
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chapters. More importantly, we were unable to estimate potential interactions between health 
conditions and methodological factors. It is possible, for example, that proxy-assessed values 
are more likely to be reported when respondents are younger, or have greater disease severity. 
This is a potential source of bias in our estimates of the impact of methodological factors on 
utility or VAS scores.  
     The number of economic evaluation of healthcare interventions in childhood populations 
has grown rapidly in recent decades, with cost-utility analysis seeing the fastest growth out of 
all evaluation techniques since 2009.74 Future economic evaluations should benefit greatly 
from our catalogue of 1,191 mean or median utility or VAS scores and from our 3,414 sets of 
statistics in the accompanying Excel database. Moreover, the results of our meta-regressions 
ensure that the utility decrements associated with health conditions adequately control for a 
range of confounding factors. However, the valuation method selected for utility inputs is a 
key methodological variable, and further research based on our database should explore the 
independent effects of valuation methods (other than the HUI3) on health utilities. A past 
review by Finnell and colleagues75 concludes that over one third of 39 paediatric cost-utility 
analyses found in the literature would reverse their result if utilities valued by SG or TTO were 
used rather than those valued by indirect valuation methods or expert opinion. Further research 
should also catalogue the effects of specific interventions or health programmes on health 
utility, as these are important inputs into decision analytic models.  
     In conclusion, this systematic review and meta-analysis of childhood utility values offers a 
wealth of resources to inform future economic evaluations within the childhood context. The 
fixed-effects approach offers a weighted average of health utilities and their distributions for 
health condition categories spanning all ICD-10 chapters relevant to childhood health, by 
valuation method. The mixed-effects meta-regression generates utility or VAS decrements for 
each condition relative to general population health after controlling for diverse methodological 
factors. Information within the appendices and the accompanying Excel database should act as 
a useful resource for analysts, as well as a basis for future methodological research studies.  
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SUPPLEMENTARY MATERIAL 
Excel database containing information on all 3,414 sub-samples of health utilities and 
descriptors can be found online at http://childhoodutilities.wordpress.com. The website also 
contains the detailed search strategy and a guidance note for Excel navigation. 
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Table 1: Number of samples by ICD-10 chapter and health condition category 
 
Health Condition Category Health Condition Sub-Category ICD-10 Code Number of 
Samples* 
General population and control group 
0. All samples   409 (112)** 
ICD-10 Chapter 1: Infectious and parasitic diseases 192 (87) 
1.1 Gastroenteritis Rotavirus gastroenteritis 1-A08 27 (12) 
 Non-rotavirus gastroenteritis 1-A09 22 (6) 
1.2 Viral infections of central 
nervous system 
Viral meningitis caused by viral 
fever 
1-A87 3 (3) 
 Combined sample of central 
nervous system infection 
(meningitis, encephalitis) 
1-A86-A87 2 (1) 
1.3 Meningococcal infection 
without permanent sequelae 
Bacterial meningococcal meningitis 1-A39 13 (5) 
1.4 Meningococcal infection 
with permanent sequelae 
Bacterial meningococcal meningitis 1-A39 42 (23) 
Meningococcal sepsis 1-A39.2 3 (3) 
 Severe meningitis (viral or bacterial 
unspecified) 
1-A39 8 (8) 
1.5 Pertussis  1-A37 28 (10) 
1.6 Viral fever  1-A99 30 (6) 
1.7 Bacteremia  1-A49 8 (8) 
1.8 Human immunodeficiency 
virus 
 1-B20 4 (2) 
1.9 Chickenpox  1-B01 2 (0) 
ICD-10 Chapter 2: Cancer 432 (150) 
2.1 Survivors of combined 
types of cancer 
 2 87 (24) 
2.2 Patients of combined types 
of cancer on active therapy 
Combined types of cancer 2 60 (19) 
Recurrent juvenile-onset respiratory 
papillomatosis 
2-D14.1 2 (2) 
2.3 Survivors of acute 
lymphoblastic leukaemia 
 2-C91 46 (22) 
2.4 Patients of acute 
lymphoblastic leukaemia on 
active therapy 
 2-C91 39 (14) 
2.5 Survivors of brain tumour Combined types of brain tumour 2-C71 105 (29) 
 Medulloblastoma 2-C71.6 15 (1) 
2.6 Patients of brain tumour on 
active therapy 
 2-C71 4 (1) 
2.7 Survivors of lymphoma Combined types of lymphoma 2-C81-C85 1 (1) 
 Hodgkin’s disease 2-C81 16 (11) 
 Non-Hodgkin’s lymphoma 2-C82-C85 4 (2) 
2.8 Patients of lymphoma on 
active therapy  
Hodgkin’s disease 2-C81 18 (3) 
2.9 Survivors of renal tumour Combined types of renal tumour 2-C64 5 (3) 
 Wilms’ tumour 2-C64 4 (4) 
2.10 Survivors of 
retinoblastoma 
 2-C69.2 3 (3) 
2.11 Survivors of sympathetic 
nervous system tumour 
Combined types of sympathetic 
nervous system tumour 
2-C74.9 1 (1) 
 Neuroblastoma 2-C74.9 6 (4) 
2.12 Survivors of other types 
of cancer 
Germ cell tumour 2-C62 2 (2) 
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 Bone tumour 2-C41 5 (1) 
 Hepatic tumour 2-C22.2 3 (1) 
 Soft tissue sarcoma 2-C49 3 (1) 
 Carcinoma 2-D00 1 (1) 
 Teratoma 2-C62.9 2 (0) 
ICD-10 Chapter 3: Diseases of the blood and immune system 73 (19) 
3.1 Haemophilia  3-D66 63 (14) 
3.2 Haemolytic anaemias Sickle cell disease 3-D57 4 (2) 
 Favism 3-D55 2 (1) 
 Thalassemia 3-D56 2 (1) 
3.3 Combined diseases of the 
blood 
 3 2 (1) 
ICD-10 Chapter 4: Endocrine, nutritional and metabolic disorders 362 (95) 
4.1 Overweight  4-E66 162 (18) 
4.2 Obese or Diabetes type II Obese 4-E66 23 (11) 
 Diabetes type II 4-E11 28 (1) 
4.3 Diabetes type I  4-E10 41 (22) 
4.4 Cystic fibrosis  4-E84 63 (21) 
4.5 Congenital adrenal 
hyperplasia 
 4-E25 12 (4) 
4.6 Hypophosphatasia  4-E83.3 6 (4) 
4.7 Phenylketonuria  4-E70 5 (3) 
4.8 Other metabolic disorders Glutaricaciduria type 1 4-E72 3 (2) 
 Long-chain acyl-CoA 
dehydrogenase deficiency 
(LCHADD) 
4-E71 5 (2) 
 Medium-chain acyl-CoA 
dehydrogenase deficiency 
(MCADD) 
4-E71 5 (2) 
 Galactosemia 4-E74.2 2 (1) 
 Mucopolysaccharidosis 4-E76 1 (1) 
 Mucopolysaccharidosis type II 
(Hunter Syndrome) 
4-E76.1 1 (1) 
 Hypothyroidism 4-E03 2 (1) 
 Combined metabolic disorders 4 3 (1) 
ICD-10 Chapter 5: Mental and behavioural disorders 537 (142) 
5.1 Attention-deficit 
hyperactivity disorder 
 5-F90 153 (48) 
5.2 Autism spectrum disorder  5-F84 7 (6) 
5.3 Pervasive developmental 
disorders other than autism 
spectrum disorder 
Asperger’s disorder 5-F84.5 2 (2) 
Combined pervasive developmental 
disorders 
5-F84 136 (4) 
5.4 Depression Depression 5-F32 58 (10) 
 Major depressive disorder 5-F33 1 (1) 
 Dysthymic disorder 5-F34 1 (1) 
5.5 Behavioural disorders Combined behavioural disorder 5-F91 4 (3) 
 Tic disorder 5-F95 2 (2) 
 Movement disorder 5-F98 1 (1) 
 Enuresis 5-F98 1 (1) 
5.6 Stress-related and 
somatoform disorders  
Combined anxiety disorders (onset 
in childhood and adolescence) 
5-F93 18 (4) 
 Social phobia 5-F93.2 1 (1) 
 Internalising disorder 5-F93 12 (1) 
 Specific phobia 5-F40.2 1 (1) 
 Panic disorder 5-F41 1 (1) 
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 Agoraphobia 5-F40 1 (1) 
 Generalised anxiety disorder 5-F41.1 1 (1) 
 Obsessive compulsive disorder 5-F42 1 (1) 
 Post-traumatic stress disorder 5-F43.1 5 (2) 
 Conversion disorder 5-F44 1 (1) 
 Hypochondriasis 5-F45.2 1 (1) 
 Victims of bullying 5 7 (3) 
5.7 Personality disorders Borderline personality disorder 5-F60.3 1 (1) 
 Avoidant personality disorder 5-F60.6 1 (1) 
 Obsessive-compulsive personality 
disorder 
5-F60.5 1 (1) 
 Depressive personality disorder 5-F60 1 (1) 
 Personality disorder, not otherwise 
specified 
5-F60 9 (1) 
5.8 Other mental disorders Combined psychiatric disorders 
(diagnosed by DSM-IV) 
5 6 (1) 
 Combined mental disorders 5 25 (2) 
 Risk of psychosis 5-F20 6 (2) 
5.9 Disorders of speech and 
language 
Receptive language disorder 5-F80.2 2 (2) 
Combined speech disorders 5-F80.9 4 (2) 
 Stuttering 5-F98.5 20 (2) 
5.10 Disorders of scholastic 
skills 
Learning disabilities 5-F81 8 (6) 
Dyslexia 5-F81 1 (1) 
5.11 Cognitive impairment  5-F06 8 (4) 
5.12 Mental retardation Mental retardation 5-F72 18 (10) 
 Motor disorder 5-F82 2 (1) 
5.13 Eating disorders  5-F50 3 (3) 
5.14 Substance use disorders  5-F10 5 (4) 
ICD-10 Chapter 6: Nervous system disorders 96 (45) 
6.1 Cerebral palsy  6-G80 31 (9) 
6.2 Muscular dystrophy Duchenne muscular dystrophy 6-G71 15 (6) 
 Muscular dystrophy and Spinal 
muscular atrophy 
6-G71/G12 2 (1) 
6.3 Epilepsy  6-G40 27 (15) 
6.4 Migraine  6-G43 5 (3) 
6.5 Hydrocephalus  6-G91 8 (7) 
6.6 Combined disorders of the 
nervous system 
Neurodevelopmental impairment 6-G96 6 (3) 
Combined rare disorders of the 
central nervous system 
6-G96 2 (1) 
ICD-10 Chapter 7: Diseases of the eye 61 (9) 
7.1 Visual disturbances and 
blindness 
 7-H54 10 (3) 
7.2 Other diseases of the eye Combined diseases of the eye 7 4 (1) 
 Nystagmus 7-H55 1 (1) 
 Visual pathway impairment 7-H47 1 (1) 
 Cataracts 7-H26 1 (1) 
 Myopia 7-H52.1 44 (2) 
ICD-10 Chapter 8: Diseases of the ear 156 (55) 
8.1 Moderate hearing loss  8-H90 56 (19) 
8.2 Severe hearing loss Severe hearing impairment 8-H90 49 (16) 
 Deafness 8-H91 4 (2) 
8.3 Acute otitis media  8-H66 16 (14) 
8.4 Otitis media with effusion  8-H65.9 31 (4) 
ICD-10 Chapter 9: Circulatory system disorders 16 (15) 
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9.1 Hypertension  9-I10 4 (4) 
9.2 Stroke  9-I64 5 (5) 
9.3 Heart disease Cardiovascular disease 9-I51 3 (2) 
 Heart failure (awaiting heart 
transplant) 
9-I50 2 (2) 
 Heart failure (after successful heart 
transplant) 
9-I50 2 (2) 
ICD-10 Chapter 10: Respiratory system disorders 175 (59) 
10.1 Chronic lower respiratory 
disease 
Asthma 10-J45 127 (25) 
Bronchitis and Emphysema 10-J40/J43 1 (1) 
10.2 Influenza and pneumonia Pneumonia 10-J12 11 (11) 
 Influenza A/H1N1 10-J09 1 (0) 
10.3 Laryngotracheal stenosis  10-J38.6 9 (7) 
10.4 Upper respiratory 
infections and diseases 
Tonsillitis 10-J03 14 (4) 
Sinusitis 10-J01 1 (1) 
 Rhinitis 10-J30 1 (1) 
10.5 Combined disorders of 
respiratory system 
Combined lung disease 10-J96 8 (8) 
Combined respiratory system 
disorders 
10 2 (1) 
ICD-10 Chapter 11: Digestive system disorders 52 (15) 
11.1 Noninfective enteritis and 
colitis 
Crohn’s disease and Ulcerative 
colitis 
11-K50-K51 20 (6) 
 Ulcerative colitis 11-K51 2 (1) 
 Food hypersensitivity 11-K52.2 1 (1) 
11.2 Congenital diaphragmatic 
hernia 
 11-K44 2 (2) 
11.3 Dental caries  11-K02 10 (1) 
11.4 Other disorders of the 
digestive system 
Liver failure (awaiting liver 
transplant) 
11-K72 1 (1) 
 Combined liver diseases 11-K76 3 (1) 
 Combined digestive disorders 11 2 (1) 
 Gastric ulcer 11-K25 1 (1) 
11.5 Celiac disease  11-K90 10 (0) 
ICD-10 Chapter 12: Diseases of the skin 26 (8) 
12.1 Atopic dermatitis  12-L20 16 (5) 
12.2 Acne  12-L70 8 (2) 
12.3 Combined skin diseases  12 2 (1) 
ICD-10 Chapter 13: Musculoskeletal system disorders 63 (21) 
13.1 Juvenile idiopathic 
arthritis 
 13-M08 15 (6) 
13.2 Scoliosis  13-M41 7 (3) 
13.3 Hip dysplasia Developmental hip dysplasia 13-M87 1 (1) 
 Legg-Calve-Perthes disease 13-M91.1 1 (1) 
 Unilateral slipped capital femoral 
epiphysis 
13-M91.1 2 (2) 
13.4 Combined 
musculoskeletal disorders 
Combined disorders 13 32 (7) 
 Back pain 13-M54 1 (1) 
ICD-10 Chapter 14: Genitourinary system disorders 55 (35) 
14.1 Kidney failure (after 
successful kidney transplant) 
 14-N17 8 (6) 
14.2 Kidney disease (before 
kidney transplant or after 
failed transplant) 
 14-N18 17 (6) 
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14.3 Inflammatory and non-
inflammatory disorders of 
female pelvic organs 
Pelvic inflammatory disease 14-N73 20 (16) 
Endometriosis 14-N80 4 (2) 
14.4 Other urogenital disorders Combined urogenital disorders 14 2 (1) 
 Urinary tract infection 14-N39 3 (3) 
 Urinary incontinence 14-N39.3 1 (1) 
ICD-10 Chapter 16: Conditions originating in the perinatal period 201 (93) 
16.1 ELBW/EPT without 
major comorbidity 
 16-P07 101 (48) 
16.2 ELBW/EPT with major 
comorbidity 
 16-P07 69 (36) 
16.3 VLBW/VPT  16-P07.1 22 (7) 
16.4 Foetal alcohol spectrum 
disorder 
 16-P04.3 9 (2) 
ICD-10 Chapter 17: Congenital malformations 85 (40) 
17.1 Spina bifida  17-Q05 30 (9) 
17.2 Craniosynostosis Apert syndrome 17-Q87 2 (2) 
 Crouzon syndrome 17-Q75.1 2 (2) 
 Muenke syndrome 17-Q75 2 (2) 
 Saethre-Chotzen syndrome 17-Q75 2 (2) 
 Combined craniosynostosis 17-Q75 4 (2) 
17.3 Other congenital limb, 
bone and facial deformities 
Combined skeletal dysplasia 17-Q77 4 (2) 
Achondroplasia 17-Q77.4 1 (1) 
 Congenital scoliosis 17-Q76.3 3 (1) 
 Combined bone deformities 17-Q77 2 (1) 
 Osteogenesis imperfecta and other 
bone deformities 
17-Q78 2 (1) 
 Congenital skeletal and facial 
conditions 
17-Q79 2 (1) 
 Congenital conditions of the 
connective tissue 
17-Q68 2 (1) 
 Arthrogryposis multiple congenital  17-Q74.3 1 (1) 
 Combined lower limb deformities 17-Q72.9 1 (1) 
17.4 Congenital malformations 
of the nervous system 
Microcephaly 17-Q02 2 (1) 
Chiari type I malformation 17-Q07 4 (1) 
17.5 Imperforate anus  17-Q42.3 8 (3) 
17.6 Chromosomal 
abnormalities 
Fragile X syndrome 17-Q99.2 3 (2) 
Down syndrome 17-Q90 2 (1) 
 Williams syndrome 17-Q93.8 2 (1) 
 Combined syndromes 17-Q99 4 (2) 
ICD-10 Chapter 19: Injury, poisoning and other consequences of external causes 295 (36) 
19.1 Survivors of combined 
types of injuries 
 19 148 (18) 
19.2 Survivors of head and 
facial injuries 
Combined head injuries 19-S00-S09 98 (4) 
Facial injury 19-S04.5 4 (1) 
19.3 Survivors of other types 
of injuries 
Burns 19-T20-T32 7 (2) 
Upper extremity fractures 19-S60-S69 4 (1) 
 Lower extremity fractures 19-S80-S89 4 (1) 
 Extremity dislocation 19 4 (1) 
 Internal organ injury 19-T06.5 4 (1) 
 Lead poisoning 19-T56 1 (1) 
19.4 Allergy Food allergy 19-T78 8 (2) 
 Combined types of allergy 19-T78.4 13 (4) 
ICD-10 Chapter 21: Contact with health services 52 (11) 
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21.1 Survivors of paediatric 
intensive care for unspecified 
reasons 
 21 43 (7) 
21.2 Unspecified organ failure 
awaiting transplant 
 21 7 (2) 
21.3 Palliative care  21 2 (2) 
Combined chronic diseases 
22. Combined types of chronic 
diseases 
  76 (26) 
  Total: 3,414 
(1,073) 
*Number of samples from whole database (Number of main sample mean utility or VAS scores, excluding main sample 
median scores). **Number of main samples of mean or median scores are: General population and control group (119); 
Chapter 1 (91); Chapter 2 (206); Chapter 3 (19); Chapter 4 (119); Chapter 5 (142); Chapter 6 (47); Chapter 7 (9); Chapter 
8 (61); Chapter 9 (15); Chapter 10 (59); Chapter 11 (26); Chapter 12 (8); Chapter 13 (21); Chapter 14 (35); Chapter 16 
(100); Chapter 17 (40); Chapter 19 (36); Chapter 21 (12); Combined chronic diseases (28); with 1,186 main samples in 
total. ELBW/EPT: Extremely-low birthweight or extremely preterm birth. VLBW/VPT: Very-low birthweight or very 
preterm birth. 
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Table 2: Characteristics of all samples (main samples) by valuation method, respondent type, 
mode of administration, age of children and country of origin  
 
Number of samples (main samples) by valuation method 
Direct valuation methods 
VAS:  
212 (118) 
EQ-5D VAS:  
231 (71) 
EQ-5D-Y VAS:  
158 (58) 
TTO:  
137 (57) 
SG:  
221 (100) 
Chained Gamble:  
143 (38) 
Indirect valuation methods 
QWB:  
218 (15) 
15D/16D/17D:  
114 (52) 
EQ-5D: 
 342 (124) 
EQ-5D-Y:  
68 (9) 
AQoL-5D:  
16 (4) 
AQoL-6D:  
41 (7) 
CHU9D:  
188 (22) 
HUI2:  
460 (195) 
HUI3:  
768 (300) 
Modified HUI:  
8 (5) 
SF-6D:  
13 (7) 
PAHOM:  
69 (5) 
Utility from 
NPB: 7 (4) 
     
Number of samples (main samples) by respondent type 
Self-assessment by children and/or 
adolescents: 1,181 (349) 
Assessment by children/adolescents 
and parents: 332 (112) 
Assessment by children/adolescents 
and caregivers: 63 (39) 
Proxy assessment by parents: 997 
(408) 
Proxy assessment by caregivers: 429 
(110) 
Proxy assessment by physicians: 196 
(100) 
Proxy assessment by physicians and 
caregivers: 29 (1) 
Proxy assessment by nurses: 76 (26) Proxy assessment by the general 
public: 20 (10) 
Proxy assessment by parents from the 
general public: 77 (35) 
Proxy assessment by adult patients: 7 
(1) 
Proxy assessment by parents, adult 
patients and the general public: 7 (0) 
Number of samples (main samples) by mode of administration 
Self-administration by respondents 
Non-postal survey: 944 (297) Postal survey: 762 (239) Online survey: 255 (51) 
Delphi process: 5 (1)   
Interview-administration 
Face-to-face interview: 1,166 (523) Telephone interview: 232 (51) Face-to-face or telephone: 15 (5) 
Mode of administration not specified: 
35 (24) 
  
Number of samples (main samples) by minimum age of children 
Minimum age of 0: 220 (96) Minimum age of 2: 246 (37) Minimum age of 5: 515 (161) 
Minimum age of 8: 875 (258) Minimum age of 12: 693 (305) Minimum age of 15: 349 (137) 
Minimum age of 18: 9 (6) Age unspecified: 508 (191)  
Number of samples (main samples) by country 
Argentina: 
2 (2) 
Australia: 
238 (37) 
Austria:  
12 (3) 
Belgium:  
2 (0) 
Brazil:  
5 (3) 
Bulgaria:  
2 (2) 
Canada:  
575 (283) 
China:  
24 (2) 
Columbia:  
12 (4) 
Cuba:  
16 (0) 
Denmark:  
10 (4) 
Finland:  
114 (52) 
France:  
3 (3) 
Germany:  
36 (18) 
Honduras:  
8 (0) 
Hungary:  
2 (2) 
India:  
2 (2) 
Iran:  
8 (4) 
Italy:  
23 (17) 
Netherlands:  
336 (109) 
New Zealand:  
14 (3) 
Portugal:  
2 (1) 
Russia:  
8 (6) 
Singapore:  
44 (2) 
South Africa:  
43 (8) 
Sweden:  
131 (50) 
Thailand:  
71 (66) 
Turkey:  
6 (5) 
UK:  
553 (193) 
Uruguay:  
12 (3) 
US:  
918 (213) 
Zimbabwe:  
4 (2) 
Developed 
countries:  
141 (65) 
Developed and 
developing:  
1 (1) 
South America:  
30 (24) 
Not specified:  
6 (2) 
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Table 3: Weighted averages of mean utility or VAS scores for each health condition category, 
by valuation method 
 
General population and control group 
0. All samples [VAS] 91.8 (1.77) 
73.3-92.7 [4] 
[EQ-5D VAS] 
93.4 (2.69) 74.6-
96.0 [5] 
[EQ-5D-Y VAS] 
86.8 (1.19) 77.3-
96.0 [20] 
[TTO] 0.982 
(0.022) 0.839-
0.985 [2] 
 [SG] 0.976 
(0.011) 0.930-
0.984 [3] 
[CG] 0.930 
(0.010) [1] 
[QWB] 0.875 
(0.001) [1] 
[15D/16D/17D] 
0.947 (0.004) 
0.933-0.989 [10] 
 [EQ-5D] 0.948 
(0.013) 0.880-
0.960 [5] 
[EQ-5D-Y] 0.875 
(0.011) 0.720-
0.889 [5] 
[AQoL-5D] 0.870 
(0.005) [1] 
[AQoL-6D] 0.855 
(0.021) 0.743-
0.890 [4] 
 [CHU9D] 0.840 
(0.012) 0.750-
0.931 [13] 
[HUI2] 0.913 
(0.012) 0.853-
0.960 [13] 
[HUI3] 0.916 
(0.010) 0.800-
0.970 [24] 
[SF-6D] 0.760 
(0.007) [1] 
ICD-10 Chapter 1: Infectious and parasitic diseases 
1.1 Gastroenteritis [VAS] 50.0 (1.54) 
41.8-50.3 [2] 
[EQ-5D VAS] 
54.8 (1.94) [1] 
[TTO] 0.931 
(0.010) 0.920-
0.940 [2] 
[CG] 0.918 
(0.015) 0.900-
0.930 [2] 
 [EQ-5D] 0.581 
(0.041) -0.208-
0.634 [9] 
[HUI2] 0.865 
(0.064) 0.735-
0.896 [2] 
  
1.2 Viral infections of central 
nervous system 
[VAS] 48.1 (3.45) 
44.7-56.3 [3] 
[HUI3] 0.174 
(0.076) [1] 
  
1.3 Meningococcal infection 
without permanent sequelae 
[CG] 0.995 
(0.002) 0.977-
0.997 [4] 
[HUI2] 0.930 
(0.009) [1] 
  
1.4 Meningococcal infection 
with permanent sequelae 
[VAS] 57.8 (9.92) 
41.5-85.4 [4] 
[EQ-5D VAS] 
47.3 (1.88) 46.0-
50.0 [2] 
[CG] 0.738 
(0.123) 0.390-
0.861 [3] 
[EQ-5D] 0.739 
(0.052) 0.020-
0.830 [6] 
 [HUI2] 0.797 
(0.041) 0.520-
0.880 [8] 
[HUI3] 0.550 
(0.092) 0.240-
0.820 [7] 
[Modified HUI] 
0.593 (0.076) 
0.440-0.780 [4] 
 
1.5 Pertussis [TTO] 0.777 
(0.068) 0.330-
0.930 [10] 
   
1.6 Viral fever [VAS] 61.6 (2.03) 
55.1-68.5 [6] 
   
1.7 Bacteremia [EQ-5D VAS] 
60.0 (1.41) 58.0-
61.0 [2] 
[EQ-5D] 0.368 
(0.018) 0.340-
0.380 [2] 
[HUI2] 0.628 
(0.034) 0.610-
0.690 [2] 
[HUI3] 0.538 
(0.026) 0.480-
0.550 [2] 
1.8 Human 
immunodeficiency virus 
[EQ-5D] 0.682 
(0.070) 0.612-
0.752 [2] 
   
ICD-10 Chapter 2: Cancer 
2.1 Survivors of combined 
types of cancer 
[15D/16D/17D] 
0.950 (0) 0.950-
0.950 [2] 
[HUI2] 0.938 
(0.008) 0.870-
0.970 [15] 
[HUI3] 0.902 
(0.025) 0.730-
0.950 [7] 
 
2.2 Patients of combined 
types of cancer on active 
therapy 
[VAS] 80.1 (5.00) 
75.0-85.0 [2] 
[TTO] 0.640 
(0.055) [1] 
[SG] 0.694 
(0.057) 0.670-
0.830 [2] 
[CG] 0.920 
(0.038) [1] 
[QWB] 0.802 
(0.029) [1] 
[HUI2] 0.773 
(0.028) 0.650-
0.840 [6] 
[HUI3] 0.693 
(0.028) 0.478-
0.760 [8] 
 
2.3 Survivors of acute 
lymphoblastic leukaemia 
[HUI2] 0.956 
(0.009) 0.871-
0.980 [11] 
[HUI3] 0.888 
(0.014) 0.722-
0.950 [11] 
  
2.4 Patients of acute 
lymphoblastic leukaemia on 
active therapy 
[EQ-5D-Y VAS] 
78.8 (2.81) 76.9-
83.0 [2] 
[HUI2] 0.792 
(0.032) 74.0-86.0 
[4] 
[HUI3] 0.809 
(0.040) 66.0-91.0 
[8] 
 
2.5 Survivors of brain 
tumour 
[HUI2] 0.857 
(0.014) 0.630-
0.940 [22] 
[HUI3] 0.744 
(0.018) 0.601-
0.830 [8] 
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2.6 Patients of brain tumour 
on active therapy 
[HUI3] 0.530 
(0.067) [1] 
   
2.7 Survivors of lymphoma [EQ-5D VAS] 
90.0 (2.40) [1] 
[HUI2] 0.873 
(0.015) 0.820-
0.930 [7] 
[HUI3] 0.857 
(0.018) 0.720-
0.940 [6] 
 
2.8 Patients of lymphoma on 
active therapy 
[EQ-5D VAS] 
61.0 (2.44) [1] 
[HUI2] 0.670 
(0.024) [1] 
[HUI3] 0.580 
(0.024) [1] 
 
2.9 Survivors of renal tumour [HUI2] 0.946 
(0.004) 0.930-
0.950 [4] 
[HUI3] 0.911 
(0.014) 0.890-
0.930 [3] 
  
2.10 Survivors of 
retinoblastoma 
[HUI2] 0.883 
(0.067) [1] 
[HUI3] 0.858 
(0.007) 0.830-
0.860 [2] 
  
2.11 Survivors of 
sympathetic nervous system 
tumour 
[HUI2] 0.895 
(0.006) 0.880-
0.900 [3] 
[HUI3] 0.878 
(0.004) 0.870-
0.880 [2] 
  
2.12 Survivors of other types 
of cancer 
[HUI3] 0.833 
(0.021) 0.490-
0.870 [5] 
   
ICD-10 Chapter 3: Diseases of the blood and immune system 
3.1 Haemophilia [VAS] 30.9 (4.33) 
23.7-38.7 [3] 
[EQ-5D VAS] 
89.1 (5.60) 80.7-
92.8 [2] 
[SG] 0.701 
(0.072) 0.487-
0.915 [6] 
[EQ-5D] 0.647 
(0.208) -0.110-
0.780 [3] 
3.2 Haemolytic anaemias [EQ-5D VAS] 
87.0 (3.60) [1] 
[TTO] 0.793 
(0.045) [1] 
[EQ-5D] 0.905 
(0.038) 0.590-
0.910 [2] 
 
3.3 Combined diseases of the 
blood 
[HUI3] 0.505 
(0.089) [1] 
   
ICD-10 Chapter 4: Endocrine, nutritional and metabolic disorders 
4.1 Overweight [EQ-5D VAS] 
78.4 (0.464) [1] 
[EQ-5D-Y VAS] 
78.5 (1.79) 74.6-
86.1 [4] 
[EQ-5D-Y] 0.853 
(0.045) 0.670-
0.890 [3] 
[AQoL-6D] 0.852 
(0.013) 0.842-
0.870 [2] 
 [CHU9D] 0.844 
(0.013) 0.810-
0.860 [4] 
[HUI2] 0.841 
(0.019) 0.838-
0.950 [2] 
[HUI3] 0.786 
(0.001) 0.780-
0.786 [2] 
 
4.2 Obese or Diabetes type II [EQ-5D VAS] 
73.2 (1.78) 69.1-
74.0 [2] 
[EQ-5D-Y VAS] 
81.9 (4.48) 75.4-
88.1 [3] 
[EQ-5D] 0.790 
(0.025) [1] 
[AQoL-6D] 0.805 
(0.011) [1] 
 [CHU9D] 0.828 
(0.001) 0.827-
0.830 [2] 
[HUI2] 0.814 
(0.009) [1] 
[HUI3] 0.820 
(0.099) 0.759-
0.980 [2] 
 
4.3 Diabetes type I [EQ-5D VAS] 
80.7 (0.147) 80.5-
80.8 [2] 
[TTO] 0.809 
(0.019) 0.530-
0.840 [7] 
[SG] 0.933 
(0.020) 0.744-
0.965 [6] 
[EQ-5D] 0.905 
(0.015) 0.765-
0.920 [4] 
 [HUI3] 0.902 
(0.027) 0.572-
0.910 [3] 
   
4.4 Cystic fibrosis [VAS] 76.0 (2.48) 
[1] 
[EQ-5D VAS] 
77.1 (1.61) [1] 
[EQ-5D-Y VAS] 
82.2 (2.99) 79.4-
85.4 [2] 
[TTO] 0.959 
(0.017) 0.700-
0.960 [2] 
 [SG] 0.920 
(0.019) [1] 
[QWB] 0.766 
(0.025) 0.611-
0.790 [5] 
[EQ-5D] 0.783 
(0.021) [1] 
[HUI2] 0.830 
(0.003) 0.800-
0.850 [4] 
 [HUI3] 0.743 
(0.009) 0.728-
0.770 [4] 
   
4.5 Congenital adrenal 
hyperplasia 
[15D/16D/17D] 
0.853 (0.030) 
0.780-0.920 [4] 
   
4.6 Hypophosphatasia [EQ-5D] 0.410 
(0.258) -0.240-
0.860 [4] 
   
4.7 Phenylketonuria [TTO] 0.397 
(0.039) [1] 
[15D/16D/17D] 
0.610 (0.030) 
0.580-0.640 [2] 
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4.8 Other metabolic disorders [TTO] 0.472 
(0.003) 0.469-
0.475 [2] 
[15D/16D/17D] 
0.643 (0.070) 
0.490-0.890 [6] 
[EQ-5D] 0.070 
(0.019) [1] 
[HUI3] 0.504 
(0.025) 0.389-
0.510 [2] 
ICD-10 Chapter 5: Mental and behavioural disorders 
5.1 Attention-deficit 
hyperactivity disorder 
[VAS] 48.3 (5.88) 
26.1-73.9 [8] 
[EQ-5D VAS] 
54.8 (7.83) 30.2-
72.4 [5] 
[TTO] 0.833 
(0.105) 0.444-
0.900 [3] 
[SG] 0.917 
(0.007) 0.880-
0.960 [10] 
 [CG] 0.812 
(0.038) 0.480-
0.920 [11] 
[EQ-5D] 0.798 
(0.012) 0.740-
0.810 [4] 
[HUI2] 0.802 
(0.020) 0.792-
0.896 [3] 
[HUI3] 0.664 
(0.034) 0.425-
0.690 [4]  
5.2 Autism spectrum disorder [EQ-5D-Y VAS] 
80.7 (0.024) [1] 
[QWB] 0.580 
(0.015) [1] 
[HUI2] 0.721 
(0.046) [1] 
[HUI3] 0.629 
(0.037) 0.431-
0.700 [4] 
5.3 Pervasive developmental 
disorders other than autism 
spectrum disorder 
[QWB] 0.595 
(0.007) 0.591-
0.620 [3] 
[HUI3] 0.674 
(0.041) 0.659-
0.790 [2] 
  
5.4 Depression [EQ-5D VAS] 
57.0 (2.00) 55.0-
59.0 [2] 
[EQ-5D] 0.892 
(0.038) 0.450-
0.910 [6] 
[NPB] 0.570 
(0.035) 0.162-
0.869 [4] 
 
5.5 Behavioural disorders [EQ-5D-Y VAS] 
76.9 (3.49) [1] 
[EQ-5D] 0.250 
(0.183) [1] 
[HUI2] 0.802 
(0.0003) 0.801-
0.802 [2] 
[HUI3] 0.620 
(0.089) 0.463-
0.727 [3] 
5.6 Stress-related and 
somatoform disorders 
[EQ-5D VAS] 
76.2 (1.99) [1] 
[EQ-5D] 0.701 
(0.056) 0.250-
0.830 [10] 
[AQoL-5D] 0.710 
(0.028) [1] 
[HUI2] 0.760 
(0.040) [1] 
 [HUI3] 0.706 
(0.012) 0.672-
0.710 [2] 
[SF-6D] 0.708 
(0.004) 0.690-
0.710 [3] 
  
5.7 Personality disorders [EQ-5D] 0.499 
(0.046) 0.340-
0.700 [5] 
   
5.8 Other mental disorders [15D/16D/17D] 
0.797 (0.002) 
0.795-0.799 [2] 
[CHU9D] 0.778 
(0.031) 0.739-
0.803 [2] 
[HUI3] 0.698 
(0.039) [1] 
 
5.9 Disorders of speech and 
language 
[EQ-5D VAS] 
88.3 (0.969) [1] 
[15D/16D/17D] 
0.941 (0.007) 
0.934-0.948 [2] 
[HUI3] 0.878 
(0.041) 0.438-
0.890 [3] 
 
5.10 Disorders of scholastic 
skills 
[VAS] 54.6 (2.92) 
51.6-61.5 [3] 
[EQ-5D-Y VAS] 
79.4 (3.02) [1] 
[EQ-5D] 0.770 
(0.018) [1] 
[HUI3] 0.397 
(0.020) 0.376-
0.417 [2] 
5.11 Cognitive impairment [HUI2] 0.738 
(0.049) 0.612-
0.757 [2] 
[HUI3] 0.592 
(0.118) 0.318-
0.643 [2] 
  
5.12 Mental retardation [EQ-5D VAS] 
56.0 (0.020) 55.0-
60.0 [2] 
[TTO] 0.510 
(0.016) [1] 
[CG] 0.590 
(0.013) [1] 
[EQ-5D] 0.117 
(0.101) 0.040-
0.250 [2] 
 [HUI2] 0.330 
(0.042) 0.300-
0.390 [2] 
[HUI3] 0.146 
(0.063) 0.010-
0.218 [3] 
  
5.13 Eating disorders [EQ-5D] 0.567 
(0.008) 0.560-
0.610 [3] 
   
5.14 Substance use disorders [EQ-5D] 0.601 
(0.165) 0.470-
0.810 [4] 
   
ICD-10 Chapter 6: Nervous system disorders 
6.1 Cerebral palsy [EQ-5D-Y VAS] 
86.3 (3.47) [1] 
[TTO] 0.550 
(0.016) [1] 
[CG] 0.600 
(0.014) [1] 
[EQ-5D] 0.922 
(0.068) [1] 
 [AQoL-5D] 0.276 
(0.030) [1] 
[HUI2] 0.125 
(0.019) [1] 
[HUI3] 0.363 
(0.045) 0.274-
0.420 [3] 
 
6.2 Muscular dystrophy [EQ-5D] 0.198 
(0.026) [1] 
[HUI3] 0.403 
(0.118) 0.100-
0.750 [6] 
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6.3 Epilepsy [EQ-5D VAS] 
73.6 (0.467) 73.0-
74.0 [2] 
[TTO] 0.710 
(0.013) [1] 
[CG] 0.700 
(0.012) [1] 
[15D/16D/17D] 
0.947 (0.011) [1] 
 [EQ-5D] 0.633 
(0.022) 0.620-
0.710 [3] 
[EQ-5D-Y] 0.530 
(0.069) [1] 
[HUI2] 0.796 
(0.005) 0.790-
0.800 [2] 
[HUI3] 0.552 
(0.098) 0.325-
0.790 [4] 
6.4 Migraine [EQ-5D VAS] 
64.3 (6.05) 62.1-
72.7 [2] 
[HUI3] 0.900 
(0.010) [1] 
  
6.5 Hydrocephalus [HUI3] 0.648 
(0.046) 0.111-
0.910 [7] 
   
6.6 Combined disorders of 
the nervous system 
[VAS] 23.1 
(0.951) 22.0-24.1 
[3] 
[HUI3] 0.280 
(0.065) [1] 
  
ICD-10 Chapter 7: Disease of the eye 
7.1 Visual disturbances and 
blindness 
[TTO] 0.810 
(0.010) [1] 
[CG] 0.810 
(0.010) [1] 
[HUI3] 0.473 
(0.077) [1] 
 
7.2 Other diseases of the eye [TTO] 0.930 
(0.0001) [1] 
[CG] 0.850 
(0.005) [1] 
[HUI3] 0.397 
(0.175) 0.050-
1.000 [4] 
 
ICD-10 Chapter 8: Diseases of the ear 
8.1 Moderate hearing loss [VAS] 54.4 (4.54) 
49.2-65.2 [3] 
[EQ-5D VAS] 
80.2 (1.46) 79.0-
82.0 [2] 
[EQ-5D-Y VAS] 
88.1 (2.77) [1] 
[QWB] 0.601 
(0.011) [1] 
 [EQ-5D] 0.850 
(0.051) 0.630-
0.880 [3] 
[HUI2] 0.639 
(0.028) 0.570-
0.650 [2] 
[HUI3] 0.601 
(0.033) 0.370-
0.820 [7] 
 
8.2 Severe hearing loss [VAS] 42.1 (4.24) 
36.8-59.0 [4] 
[TTO] 0.855 
(0.024) 0.750-
0.860 [2] 
[CG] 0.860 
(0.009) [1] 
[HUI3] 0.496 
(0.049) 0.250-
0.830 [11] 
8.3 Acute otitis media [VAS] 72.8 (4.92) 
53.0-79.0 [4] 
[EQ-5D VAS] 
65.4 ((1.29) 65.0-
70.0 [2] 
[TTO] 0.970 
(0.008) [1] 
[CG] 0.960 
(0.007) [1] 
 [EQ-5D] 0.610 
(0) 0.610-0.610 
[2] 
[HUI2] 0.731 
(0.056) 0.650-
0.770 [2] 
[HUI3] 0.673 
(0.078) 0.510-
0.710 [2] 
 
8.4 Otitis media with 
effusion 
[EQ-5D] 0.884 
(0.039) [1] 
[HUI2] 0.879 
(0.009) 0.849-
0.882 [2] 
[HUI3] 0.829 
(0.011) [1] 
 
ICD-10 Chapter 9: Circulatory system disorders 
9.1 Hypertension [VAS] 48.9 (2.71) 
45.1-54.3 [3] 
[HUI3] 0.700 
(0.115) [1] 
  
9.2 Stroke [VAS] 30.0 (1.00) 
29.0-31.0 [2] 
[SG] 0.772 
(0.020) 0.750-
0.790 [2] 
[HUI3] 0.790 
(0.113) [1] 
 
9.3 Heart disease [15D/16D/17D] 
0.940 [1] 
[HUI2] 0.107 
(0.136) 0.050-
0.760 [3] 
[HUI3] 0.766 
(0.187) 0.484-
0.890 [2] 
 
ICD-10 Chapter 10: Respiratory system disorders 
10.1 Chronic lower 
respiratory disease 
[VAS] 65.9 
(0.555) 64.0-66.3 
[3] 
[EQ-5D VAS] 
89.2 (2.67) 79.6-
89.9 [2] 
[EQ-5D-Y VAS] 
82.6 (2.16) 80.7-
85.0 [2] 
[TTO] 0.850 
(0.011) [1] 
 [SG] 0.910 
(0.011) 0.820-
0.933 [7] 
[CG] 0.830 
(0.011) [1] 
[EQ-5D] 0.901 
(0.020) 0.880-
0.920 [2] 
[HUI3] 0.903 
(0.028) 0.553-
0.930 [3] 
 [Modified HUI] 
0.890 (0.012) [1] 
[PAHOM] 0.837 
(0.058) 0.700-
0.950 [4] 
  
10.2 Influenza and 
pneumonia 
[VAS] 74.8 (4.20) 
66.9-83.1 [3] 
[EQ-5D VAS] 
67.6 (1.66) 67.0-
72.0 [2] 
[EQ-5D] 0.477 
(0.007) 0.460-
0.480 [2] 
[HUI2] 0.695 
(0.011) 0.690-
0.720 [2] 
 [HUI3] 0.572 
(0.019) 0.530-
0.580 [2] 
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10.3 Laryngotracheal 
stenosis 
[VAS] 90.5 
(0.767) 90.0-93.0 
[3] 
[15D/16D/17D] 
0.869 (0.050) [1] 
[HUI3] 0.896 
(0.038) 0.840-
0.970 [3] 
 
10.4 Upper respiratory 
infections and diseases 
[EQ-5D VAS] 
92.3 (0.417) [1] 
[CG] 0.897 
(0.064) 0.776-
0.931 [2] 
[15D/16D/17D] 
0.933 (0.002) 
0.930-0.935 [2] 
[HUI3] 0.930 
(0.014) [1] 
10.5 Combined disorders of 
respiratory system 
[EQ-5D VAS] 
67.2 (1.85) 66.0-
70.0 [2] 
[EQ-5D] 0.572 
(0.052) 0.500-
0.610 [2] 
[HUI2] 0.715 
(0.005) 0.710-
0.720 [2] 
[HUI3] 0.552 
(0.035) 0.464-
0.580 [3] 
ICD-10 Chapter 11: Digestive system disorders 
11.1 Noninfective enteritis 
and colitis 
[VAS] 77.6 (1.98) 
[1] 
[EQ-5D VAS] 
91.8 (2.71) 73.6-
92.2 [2] 
[TTO] 0.923 
(0.021) [1] 
[SG] 0.971 
(0.009) [1] 
 [15D/16D/17D] 
0.935 (0.017) 
0.880-0.950 [3] 
   
11.2 Congenital 
diaphragmatic hernia 
[EQ-5D] 0.910 
(0.104) [1] 
[HUI3] 0.906 
(0.023) [1] 
  
11.3 Dental caries [CHU9D] 0.880 
(0.009) [1] 
   
11.4 Other disorders of the 
digestive system 
[15D/16D/17D] 
0.930 [1] 
[HUI2] 0.860 [1] [HUI3] 0.882 
(0.075) 0.575-
0.900 [2] 
 
ICD-10 Chapter 12: Diseases of the skin 
12.1 Atopic dermatitis [VAS] 59.1 (5.12) 
58.1-86.3 [2] 
[EQ-5D VAS] 
92.2 (0.404) [1] 
[EQ-5D] 0.690 
(0.028) [1] 
[PAHOM] 0.690 
(0.019) [1] 
12.2 Acne [TTO] 0.961 
(0.006) [1] 
[HUI3] 0.920 
(0.098) [1] 
  
12.3 Combined skin diseases [HUI3] 0.621 
(0.073) [1] 
   
ICD-10 Chapter 13: Musculoskeletal system disorders 
13.1 Juvenile idiopathic 
arthritis 
[EQ-5D-Y VAS] 
65.6 (4.16) [1] 
[EQ-5D] 0.837 
(0.104) 0.630-
0.889 [2] 
[HUI3] 0.730 
(0.134) 0.415-
0.880 [3] 
 
13.2 Scoliosis [EQ-5D] 0.699 
(0.129) 0.100-
0.760 [3] 
   
13.3 Hip dysplasia [EQ-5D VAS] 
85.9 (5.63) [1] 
[HUI3] 0.830 
(0.040) [1] 
[SF-6D] 0.894 
(0.028) 0.870-
0.926 [2] 
 
13.4 Combined 
musculoskeletal disorders 
[VAS] 76.5 
(0.820) 75.0-77.7 
[3] 
[SG] 0.935 
(0.012) [1] 
[CG] 0.904 
(0.009) 0.890-
0.910 [2] 
[HUI3] 0.866 
(0.039) 0.762-
0.880 [2] 
ICD-10 Chapter 14: Genitourinary system disorders 
14.1 Kidney failure (after 
successful kidney transplant) 
[VAS] 83.0 (2.71) 
[1] 
[TTO] 0.990 
(0.0002) [1] 
[15D/16D/17D] 
0.885 (0.035) 
0.850-0.920 [2] 
[HUI2] 0.863 
(0.032) [1] 
 [HUI3] 0.854 
(0.042) [1] 
   
14.2 Kidney disease (before 
kidney transplant or after 
failed transplant) 
[VAS] 55.0 (4.23) 
[1] 
[TTO] 0.620 
(0.085) [1] 
[HUI2] 0.720 
(0.056) [1] 
[HUI3] 0.714 
(0.053) [2] 
[SF-6D] 0.700 
(0.027) [1] 
   
14.3 Inflammatory and non-
inflammatory disorders of 
female pelvic organs 
[VAS] 62.0 (3.33) 
47.9-73.8 [8] 
[EQ-5D VAS] 
39.2 (5.68) [1] 
[TTO] 0.856 
(0.019) 0.760-
0.910 [8] 
[EQ-5D] 0.750 
(0.057) [1] 
14.4 Other urogenital 
disorders 
[VAS] 65.4 
(0.783) 64.5-67.1 
[3] 
[HUI3] 0.879 
(0.105) 0.611-
0.920 [2] 
  
ICD-10 Chapter 16: Conditions originating in the perinatal period 
16.1 ELBW/EPT without 
major comorbidity 
[VAS] 75.2 (6.58) 
50.0-87.0 [5] 
[SG] 0.818 
(0.025) 0.540-
0.960 [22]  
[HUI2] 0.895 
(0.020) 0.800-
0.955 [8] 
[HUI3] 0.873 
(0.020) 0.750-
0.959 [13] 
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16.2 ELBW/EPT with major 
comorbidity 
[VAS] 26.3 (2.70) 
21.0-34.0 [4] 
[SG] 0.206 
(0.043) -0.070-
0.780 [17] 
[CG] 0.900 
(0.017) [1] 
[HUI2] 0.821 
(0.032) 0.612-
0.890 [6] 
 [HUI3] 0.726 
(0.039) 0.318-
0.800 [8] 
   
16.3 VLBW/VPT [15D/16D/17D] 
0.943 (0.011) [1] 
[HUI3] 0.884 
(0.012) 0.840-
0.930 [6] 
  
16.4 Foetal alcohol spectrum 
disorder 
[HUI3] 0.475 
(0.030) 0.440-
0.500 [2] 
   
ICD-10 Chapter 17: Congenital malformations 
17.1 Spina bifida [EQ-5D-Y VAS] 
76.9 (6.52) [1] 
[AQoL-5D] 0.370 
(0.041) [1] 
[HUI2] 0.550 
(0.027) [1] 
[HUI3] 0.521 
(0.019) 0.448-
0.800 [6] 
17.2 Craniosynostosis [VAS] 84.3 (2.00) 
77.0-88.0 [5] 
[HUI3] 0.791 
(0.055) 0.440-
0.870 [5] 
  
17.3 Other congenital limb, 
bone and facial deformities 
[EQ-5D-Y VAS] 
90.1 (3.49) 78.8-
93.0 [3] 
[15D/16D/17D] 
0.912 (0.004) 
0.908-0.916 [2] 
[EQ-5D] 0.740 
(0.070) [1] 
[HUI3] 0.413 
(0.022) 0.376-
0.471 [4] 
17.4 Congenital 
malformations of the nervous 
system 
[HUI3] 0.575 
(0.222) 0.180-
0.700 [2] 
   
17.5 Imperforate anus [EQ-5D VAS] 
84.1 (0.924) [1] 
[EQ-5D] 0.880 
(0.001) 0.880-
0.890 [2] 
  
17.6 Chromosomal 
abnormalities 
[EQ-5D] 0.460 
(0.032) [1] 
[HUI3] 0.276 
(0.044) 0.162-
0.360 [5] 
  
ICD-10 Chapter 19: Injury, poisoning and other consequences of external causes 
19.1 Survivors of combined 
types of injuries 
[VAS] 14.8 (4.45) 
11.0-20.0 [2] 
[EQ-5D VAS] 
86.8 (2.96) 78.3-
90.5 [4] 
[SG] 0.586 
(0.020) 0.570-
0.610 [2] 
[QWB] 0.698 
(0.021) 0.672-
0.715 [2] 
 [EQ-5D] 0.904 
(0.017) 0.610-
0.930 [7] 
[HUI3] 0.875 
(0.007) [1] 
  
19.2 Survivors of head and 
facial injuries 
[QWB] 0.508 
(0.028) [1] 
[EQ-5D] 0.959 
(0.025) 0.930-
0.980 [2] 
[HUI2] 0.400 
(0.017) [1] 
[HUI3] 0.345 
(0.098) [1] 
19.3 Survivors of other types 
of injuries 
[VAS] 77.0 (3.88) 
[1] 
[15D/16D/17D] 
0.962 (0.028) [1] 
[EQ-5D] 0.889 
(0.014) 0.850-
0.920 [5] 
 
19.4 Allergy [EQ-5D VAS] 
92.6 (0.270) [1] 
[TTO] 0.910 
(0.010) [1] 
[CG] 0.910 
(0.008) [1] 
[EQ-5D] 0.840 
(0.012) [1] 
 [HUI3] 0.917 
(0.007) 0.900-
0.920 [2] 
   
ICD-10 Chapter 21: Contact with health services 
21.1 Survivors of paediatric 
intensive care for unspecified 
reasons 
[VAS] 70.0 (11.2) 
[1] 
[TTO] 0.910 
(0.009) [1] 
[CG] 0.870 
(0.010) [1]  
[HUI2] 0.780 
(0.029) [1] 
[HUI3] 0.725 
(0.067) 0.580-
0.810 [3] 
   
21.2 Unspecified organ 
failure awaiting transplant 
[15D/16D/17D] 
0.885 (0.006) 
0.874-0.888 [2] 
   
21.3 Palliative care [HUI2] 0.370 
(0.028) [1] 
[HUI3] 0.150 
(0.042) [1] 
  
Combined chronic diseases 
22. Combined types of 
chronic diseases 
[VAS] 79.4 (1.03) 
76.0-80.0 [3] 
[EQ-5D VAS] 
72.9 (0.267) 71.7-
73.0 [2] 
[EQ-5D-Y VAS] 
84.4 (2.54) 74.6-
88.4 [4] 
[TTO] 0.890 
(0.024) 0.770-
0.920 [3] 
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 [SG] 0.924 
(0.003) 0.920-
0.930 [3] 
[CG] 0.960 
(0.016) [1] 
[15D/16D/17D] 
0.895 (0.013) [1] 
[EQ-5D] 0.800 
(0.012) [1] 
 [HUI2] 0.884 
(0.034) 0.760-
0.950 [4] 
[HUI3] 0.834 
(0.098) 0.142-
0.920 [4] 
  
[Valuation method] Mean (Standard error) Range [Number of samples]. VAS scores expressed to three significant figures; 
utility values expressed to three decimal places. Where two or more samples are used to calculate the weighted average, 
standard error measures the degree of variation between samples. Where only one sample is used, the standard error of the 
sample mean is taken. CG: Chained Gamble. ELBW/EPT: Extremely-low birthweight or extremely preterm birth. 
VLBW/VPT: Very-low birthweight or very preterm birth. 
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Table 4: Meta-regression of main health utility samples measured using the HUI3; hierarchical 
linear model  
 
Variable Coefficient 
Robust standard 
error 
95% confidence 
interval P value 
Constant (Baseline scenario) 0.876 0.045 0.788 to 0.965 <0.001 
ICD-10 Chapter 1: Infectious and parasitic diseases 
1.2 Viral infections of central nervous system -0.568 0.059 -0.684 to -0.452 <0.001 
1.4 Meningococcal infection with permanent 
sequelae 
-0.424 0.071 -0.564 to -0.285 <0.001 
1.7 Bacteremia -0.295 0.071 -0.434 to -0.156 <0.001 
ICD-10 Chapter 2: Cancer     
2.1 Survivors of combined types of cancer 0.019 0.028 -0.036 to 0.073 0.498 
2.2 Patients of combined types of cancer on 
active therapy 
-0.298 0.041 -0.378 to -0.218 <0.001 
2.3 Survivors of acute lymphoblastic leukaemia 0.024 0.006 0.013 to 0.036 <0.001 
2.4 Patients of acute lymphoblastic leukaemia 
on active therapy 
-0.202 0.006 -0.213 to -0.190 <0.001 
2.5 Survivors of brain tumour -0.074 0.004 -0.081 to -0.066 <0.001 
2.6 Patients of brain tumour on active therapy -0.480 0.028 -0.534 to -0.425 <0.001 
2.7 Survivors of lymphoma 0.025 0.005 0.016 to 0.035 <0.001 
2.8 Patients of lymphoma on active therapy -0.334 0.005 -0.344 to -0.325 <0.001 
2.9 Survivors of renal tumour 0.067 0.003 0.061 to 0.073 <0.001 
2.10 Survivors of retinoblastoma 0.037 0.003 0.032 to 0.043 <0.001 
2.11 Survivors of sympathetic nervous system 
tumour 
0.057 0.003 0.051 to 0.063 <0.001 
2.12 Survivors of other types of cancer 0.015 0.003 0.009 to 0.020 <0.001 
ICD-10 Chapter 3: Diseases of the blood and immune system 
3.3 Combined diseases of the blood -0.237 0.059 -0.353 to -0.121 <0.001 
ICD-10 Chapter 4: Endocrine, nutritional and metabolic disorders 
4.1 Overweight -0.015 0.005 -0.025 to -0.006 0.002 
4.2 Obese or Diabetes type II -0.032 0.019 -0.069 to 0.005 0.087 
4.3 Diabetes type I -0.230 0.037 -0.301 to -0.158 <0.001 
4.4 Cystic fibrosis -0.014 0.059 -0.130 to 0.102 0.807 
4.8 Other metabolic disordersa -0.413 0.036 -0.484 to -0.342 <0.001 
ICD-10 Chapter 5: Mental and behavioural disorders 
5.1 Attention-deficit hyperactivity disorder -0.369 0.039 -0.445 to -0.292 <0.001 
5.2 Autism spectrum disorder -0.367 0.036 -0.438 to -0.297 <0.001 
5.3 Other pervasive developmental disordersb -0.258 0.035 -0.327 to -0.189 <0.001 
5.5 Behavioural disorders -0.318 0.048 -0.412 to -0.225 <0.001 
5.6 Stress-related and somatoform disorders -0.272 0.015 -0.301 to -0.243 <0.001 
5.8 Other mental disordersc -0.247 0.014 -0.274 to -0.219 <0.001 
5.9 Disorders of speech and language -0.364 0.036 -0.435 to -0.292 <0.001 
5.10 Disorders of scholastic skills -0.376 0.047 -0.468 to -0.284 <0.001 
5.11 Cognitive impairment -0.400 0.014 -0.427 to -0.372 <0.001 
5.12 Mental retardation -0.600 0.033 -0.664 to -0.536 <0.001 
ICD-10 Chapter 6: Nervous system disorders 
6.1 Cerebral palsy -0.528 0.036 -0.599 to -0.457 <0.001 
6.2 Muscular dystrophy -0.358 0.059 -0.474 to -0.242 <0.001 
6.3 Epilepsy -0.324 0.123 -0.565 to -0.083 0.008 
6.4 Migraine -0.068 0.026 -0.119 to -0.017 0.009 
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6.5 Hydrocephalus -0.629 0.060 -0.748 to -0.511 <0.001 
6.6 Other disorders of the nervous systemd -0.462 0.059 -0.578 to -0.346 <0.001 
ICD-10 Chapter 7: Diseases of the eye     
7.1 Vision loss -0.329 0.036 -0.400 to -0.258 <0.001 
7.2 Other diseases of the eyee 0.031 0.027 -0.022 to 0.084 0.249 
ICD-10 Chapter 8: Diseases of the ear     
8.1 Moderate hearing loss  -0.284 0.057 -0.395 to -0.173 <0.001 
8.2 Severe hearing loss -0.360 0.056 -0.470 to -0.250 <0.001 
8.3 Acute otitis media -0.178 0.071 -0.317 to -0.039 0.012 
8.4 Otitis media with effusion 0.008 0.047 -0.084 to 0.099 0.864 
ICD-10 Chapter 9: Circulatory system disorders 
9.1 Hypertension -0.168 0.026 -0.219 to -0.117 <0.001 
9.2 Stroke -0.178 0.026 -0.229 to -0.127 <0.001 
9.3 Heart disease -0.158 0.104 -0.362 to 0.045 0.128 
ICD-10 Chapter 10: Respiratory system disorders 
10.1 Chronic lower respiratory diseases -0.074 0.049 -0.169 to 0.021 0.127 
10.2 Influenza and pneumonia -0.259 0.071 -0.397 to -0.120 <0.001 
10.3 Laryngotracheal stenosis 0.044 0.022 0.000 to 0.087 0.043 
10.4 Upper respiratory infections and diseases -0.038 0.026 -0.089 to 0.013 0.147 
10.5 Combined disorders of the respiratory 
system 
-0.273 0.065 -0.399 to -0.146 <0.001 
ICD-10 Chapter 11: Digestive system disorders 
11.2 Congenital diaphragmatic hernia 0.047 0.024 0.001 to 0.094 0.042 
11.4 Other disorders of the digestive systemf -0.091 0.058 -0.205 to 0.024 0.121 
ICD-10 Chapter 12: Diseases of the skin     
12.2 Acne -0.048 0.026 -0.099 to 0.003 0.067 
12.3 Combined skin diseases -0.181 0.036 -0.252 to -0.110 <0.001 
ICD-10 Chapter 13: Musculoskeletal system disorders 
13.1 Juvenile idiopathic arthritis -0.155 0.104 -0.359 to 0.049 0.136 
13.3 Hip dysplasia 0.028 0.025 -0.022 to 0.077 0.272 
13.4 Combined musculoskeletal disordersg -0.088 0.026 -0.139 to -0.037 0.001 
ICD-10 Chapter 14: Genitourinary system disorders 
14.1 Kidney failure (after successful kidney 
transplant) 
0.111 0.046 0.020 to 0.201 0.016 
14.2 Kidney disease (before kidney transplant 
or after failed transplant) 
-0.138 0.059 -0.254 to -0.022 0.019 
14.4 Other urogenital disordersh -0.094 0.074 -0.238 to 0.050 0.202 
ICD-10 Chapter 16: Conditions originating in the perinatal period 
16.1 ELBW/EPT without major comorbidity -0.081 0.037 -0.154 to -0.009 0.029 
16.2 ELBW/EPT with major comorbidity -0.268 0.065 -0.396 to -0.141 <0.001 
16.3 VLBW/VPT -0.021 0.014 -0.047 to 0.006 0.126 
16.4 Foetal alcohol spectrum disorder -0.330 0.025 -0.379 to -0.281 <0.001 
ICD-10 Chapter 17: Congenital malformations 
17.1 Spina bifida -0.294 0.059 -0.410 to -0.178 <0.001 
17.2 Craniosynostosis -0.146 0.046 -0.236 to -0.057 0.001 
17.3 Other congenital limb, bone and facial 
deformitiesi 
-0.344 0.053 -0.448 to -0.240 <0.001 
17.4 Congenital malformations of the nervous 
system 
-0.622 0.036 -0.693 to -0.551 <0.001 
17.6 Chromosomal abnormalities -0.504 0.045 -0.593 to -0.416 <0.001 
ICD-10 Chapter 19: Injury, poisoning and other consequences of external causes 
19.1 Survivors of combined types of injuries -0.067 <0.001 -0.067 to -0.067 <0.001 
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19.2 Survivors of head and facial injuries -0.397 0.059 -0.513 to -0.281 <0.001 
19.4 Allergy -0.054 0.026 -0.105 to -0.003 0.039 
ICD-10 Chapter 21: Contact with health services 
21.1 Survivors of paediatric intensive care for 
unspecified reasons 
-0.258 0.041 -0.338 to -0.178 <0.001 
21.3 Palliative care -0.859 0.028 -0.913 to -0.804 <0.001 
Combined chronic diseases     
22. Combined types of chronic diseases -0.642 0.054 -0.748 to -0.536 <0.001 
Dummy for hypothetical health state -0.098 0.078 -0.251 to 0.054 0.205 
Respondent types. Baseline: Self-assessment by children/adolescents 
Assessed together by children/adolescents and 
parents or by children/adolescents and 
caregivers 
-0.055 0.016 -0.086 to -0.025 <0.001 
Proxy-assessment by parents 0.041 0.012 0.017 to 0.065 0.001 
Proxy-assessment by caregivers -0.053 0.015 -0.082 to -0.024 <0.001 
Proxy-assessment by physicians or by 
physicians and caregivers 
0.090 0.047 -0.001 to 0.182 0.054 
Proxy-assessment by nurses 0.121 0.139 -0.153 to 0.394 0.387 
Administration modes. Baseline: Self-administered in health or school setting 
Self-administered postal survey 0.043 0.044 -0.042 to 0.129 0.323 
Self-administered online survey -0.015 0.053 -0.119 to 0.088 0.772 
Face-to-face interview -0.019 0.044 -0.104 to 0.067 0.669 
Telephone interview 0.151 0.047 0.059 to 0.244 0.001 
Administration mode not specified 0.061 0.045 -0.026 to 0.148 0.170 
Dummy for samples with minimum age 
greater than 12 
-0.060 0.028 -0.115 to -0.005 0.033 
Dummy for samples from developing 
countries 
-0.057 0.046 -0.147 to 0.034 0.219 
Note. 278 samples across 88 studies included. Dependent variable: mean HUI3. Individual mean HUI3 utilities weighted by 
inverse of standard error and each study weighted by total number of respondents. Baseline scenario (interpretation of 
constant): samples with general population health, self-assessed by children/adolescents, self-administered survey (non-
postal questionnaire or Delphi process), non-hypothetical health state, minimum age less than 12 and from developed 
countries (Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, New Zealand, 
Portugal, Singapore, Sweden, UK and US). ELBW/EPT: Extremely-low birthweight or extremely preterm birth. 
VLBW/VPT: Very-low birthweight or very preterm birth. Main samples using HUI3 included in the following categories: 
aCategory 4.8 – Mucopolysaccharidosis type II (Hunter Syndrome) and Combined metabolic disorders; bCategory 5.3 –  
Asperger’s syndrome and Combined pervasive developmental disorders; cCategory 5.8 – Combined psychiatric disorders 
(diagnosed by DSM-IV); dCategory 6.6 – Combined rare disorders of the central nervous system; eCategory 7.2 – Combined 
disorders of eye, Nystagmus, Visual pathway impairment and Cataracts; fCategory 11.4 – Gastric ulcer and Combined 
digestive disorders; gCategory 13.4 – Back pain and Combined musculoskeletal disorders; hCategory 14.4 – Combined 
urogenital disorders and Urinary incontinence; iCategory 17.3 – Combined bone deformities, Osteogenesis imperfecta and 
other bone deformities, Congenital skeletal and facial conditions and Congenital conditions of the connective tissue.  
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Table 5: Meta-regression of main health utility samples measured using a VAS; hierarchical 
linear model 
 
Variable Coefficient 
Robust standard 
error 
95% confidence 
interval P value 
Constant (Baseline scenario) 82.88 1.28 80.36 to 85.39 <0.001 
ICD-10 Chapter 1: Infectious and parasitic diseases 
1.1 Gastroenteritis -39.80 2.53 -44.75 to -34.84 <0.001 
1.2 Viral infections of central nervous system -21.58 5.90 -33.14 to -10.03 <0.001 
1.4 Meningococcal infection with permanent 
sequelae 
-22.66 6.29 -34.99 to -10.33 <0.001 
1.6 Viral fever -8.43 5.90 -19.99 to 3.13 0.153 
1.7 Bacteremia -20.01 5.64 -31.05 to -8.96 <0.001 
ICD-10 Chapter 2: Cancer     
2.2 Patients of combined types of cancer on 
active therapy 
-3.80 1.63 -7.00 to -0.60 0.020 
2.4 Patients of acute lymphoblastic leukaemia on 
active therapy 
-9.31 3.07 -15.32 to -3.30 0.002 
2.7 Survivors of lymphoma 12.58 2.45 7.77 to 17.38 <0.001 
2.8 Patients of lymphoma on active therapy -16.42 2.45 -21.23 to -11.62 <0.001 
ICD-10 Chapter 3: Diseases of the blood and immune system 
3.1 Haemophilia -25.17 13.86 -52.34 to 2.00 0.069 
3.2 Haemolytic anaemias -9.00 <0.001 -9.00 to -9.00 <0.001 
ICD-10 Chapter 4: Endocrine, nutritional and metabolic disorders 
4.1 Overweight -3.28 0.59 -4.44 to -2.12 <0.001 
4.2 Obese or Diabetes type II -6.32 1.33 -8.92 to -3.72 <0.001 
4.3 Diabetes type I -12.63 3.16 -18.81 to -6.44 <0.001 
4.4 Cystic fibrosis -0.38 2.39 -5.06 to 4.30 0.873 
ICD-10 Chapter 5: Mental and behavioural disorders 
5.1 Attention-deficit hyperactivity disorder -26.88 4.72 -36.13 to -17.62 <0.001 
5.2 Autism spectrum disorder -10.88 5.48 -21.62 to -0.15 0.047 
5.4 Depression -26.44 2.54 -31.42 to -21.46 <0.001 
5.5 Behavioural disorders -20.14 6.06 -32.02 to -8.25 0.001 
5.6 Stress-related and somatoform disorders -2.41 4.79 -11.79 to 6.97 0.615 
5.9 Disorders of speech and language -1.97 2.48 -6.83 to 2.89 0.427 
5.10 Disorders of scholastic skills -14.73 6.06 -26.61 to -2.85 0.015 
5.12 Mental retardation -21.35 5.75 -32.61 to -10.08 <0.001 
ICD-10 Chapter 6: Nervous system disorders 
6.1 Cerebral palsy -7.23 3.19 -13.48 to -0.97 0.024 
6.3 Epilepsy -6.72 5.61 -17.72 to 4.29 0.232 
6.4 Migraine -23.16 2.25 -27.56 to -18.75 <0.001 
6.6 Combined disorders of the nervous system -47.05 5.90 -58.61 to -35.50 <0.001 
ICD-10 Chapter 8: Diseases of the ear     
8.1 Moderate hearing loss  -11.71 7.21 -25.85 to 2.43 0.104 
8.2 Severe hearing loss -30.63 5.70 -41.80 to -19.47 <0.001 
8.3 Acute otitis media -12.77 5.63 -23.81 to -1.72 0.023 
ICD-10 Chapter 9: Circulatory system disorders 
9.1 Hypertension -20.75 5.90 -32.31 to -9.20 <0.001 
9.2 Stroke -20.82 4.97 -30.56 to -11.09 <0.001 
ICD-10 Chapter 10: Respiratory system disorders 
10.1 Chronic lower respiratory disease -5.71 0.20 -6.10 to -5.31 <0.001 
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10.2 Influenza and pneumonia 3.05 6.07 -8.84 to 14.94 0.615 
10.3 Laryngotracheal stenosis -0.56 2.76 -5.97 to 4.86 0.841 
10.4 Upper respiratory infections and diseases -3.42 0.09 -3.59 to -3.25 <0.001 
10.5 Combined disorders of the respiratory 
system 
-12.11 5.64 -23.16 to -1.05 0.032 
ICD-10 Chapter 11: Digestive system disorders 
11.1 Noninfective enteritis and colitis -3.57 0.08 -3.73 to -3.42 <0.001 
ICD-10 Chapter 12: Diseases of the skin     
12.1 Atopic dermatitis -3.51 0.11 -3.72 to -3.30 <0.001 
ICD-10 Chapter 13: Musculoskeletal system disorders 
13.1 Juvenile idiopathic arthritis -28.23 3.19 -34.48 to -21.97 <0.001 
13.3 Hip dysplasia 2.48 2.54 -2.50 to 7.47 
0.328 
 
13.4 Combined musculoskeletal disordersa -17.39 2.30 -21.89 to -12.89 
<0.001 
 
ICD-10 Chapter 14: Genitourinary system disorders 
14.1 Kidney failure (after successful kidney 
transplant) 
-1.60 4.24 -9.92 to 6.72 0.706 
14.2 Kidney disease (before kidney transplant or 
after failed transplant) 
-29.60 4.24 -37.92 to -21.28 <0.001 
14.3 Inflammatory and non-inflammatory 
disorders of female pelvic organs 
7.52 3.25 1.14 to 13.89 0.021 
14.4 Other urogenital disordersb -4.70 5.90 -16.25 to 6.86 0.426 
ICD-10 Chapter 16: Certain conditions originating in the perinatal period 
16.1 ELBW/EPT without major comorbidity -0.65 3.57 -7.65 to 6.35 0.856 
16.2 ELBW/EPT with major comorbidity -43.05 3.61 -50.14 to -35.97 <0.001 
ICD-10 Chapter 17: Congenital malformations 
17.1 Spina bifida -16.93 3.19 -23.18 to -10.67 <0.001 
17.2 Craniosynostosis -6.91 2.48 -11.76 to -2.05 0.005 
17.3 Other congenital limb, bone and facial 
deformitiesc 
-5.91 3.19 -12.17 to 0.34 0.064 
17.5 Imperforate anus 3.85 4.71 -5.38 to 13.07 0.414 
ICD-10 Chapter 19: Injury, poisoning and other consequences of external causes 
19.1 Survivors of combined types of injuries -10.08 11.58 -32.77 to 12.62 0.384 
19.3 Survivors of other types of injuries 1.46 4.16 -6.68 to 9.61 0.725 
19.4 Allergy -3.12 0.09 -3.29 to -2.95 <0.001 
ICD-10 Chapter 21: Contact with health services 
21.1 Survivors of paediatric intensive care for 
unspecified reasons 
-20.34 2.48 -25.20 to -15.48 <0.001 
Combined chronic diseases     
22. Combined types of chronic diseases -2.95 0.31 -3.56 to -2.34 <0.001 
Dummy for hypothetical health states -20.51 3.60 -27.56 to -13.46 <0.001 
Respondent types. Baseline: Self-assessment by children/adolescents 
Assessed together by children/adolescents and 
parents or by children/adolescents and caregivers 
1.19 4.87 -8.35 to 10.72 0.807 
Proxy-assessment by parents 7.43 2.67 2.21 to 12.66 0.005 
Proxy-assessment by caregivers -3.04 4.97 -12.78 to 6.69 0.540 
Proxy-assessment by physicians or by physicians 
and caregivers 
13.17 2.63 8.01 to 18.33 <0.001 
Proxy-assessment by nurses -1.48 2.43 -6.24 to 3.28 0.543 
Proxy-assessment by general public, by parents 
from general public or by adult patients 
7.02 2.64 1.85 to 12.19 0.008 
Administration modes. Baseline: Self-administered in health or school setting 
Self-administered postal survey 4.63 2.44 -0.15 to 9.41 0.058 
Self-administered online survey -7.91 4.18 -16.10 to 0.27 0.058 
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Face-to-face interview 5.99 2.34 1.40 to 10.58 0.011 
Administration mode not specified 18.58 2.45 13.77 to 23.38 <0.001 
Dummy for samples with minimum age 
greater than 12 
-5.45 2.44 -10.24 to -0.67 0.026 
Dummy for samples from developing 
countries 
-0.49 2.52 -5.43 to 4.45 0.847 
Note. 212 samples across 66 studies included. Dependent variable: mean VAS. Individual mean VAS score weighted by 
inverse of standard error and each study weighted by total number of respondents. Baseline scenario (interpretation of 
constant): samples with general population health, self-assessed by children/adolescents, self-administered survey (non-
postal questionnaire or Delphi process), non-hypothetical health state, minimum age less than 12 and from developed 
countries (Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, New Zealand, 
Portugal, Singapore, Sweden, UK and US). ELBW/EPT: Extremely-low birthweight or extremely preterm birth. Main 
samples using VAS included in the following categories: aCategory 13.4 – Combined musculoskeletal disorders; bCategory 
14.4 – Urinary tract infection; cCategory 17.3 – Achondroplasia, Arthrogryposis multiple congenital and Combined lower 
limb deformities 
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Figure 1: PRISMA flow diagram 
 
Note. PRISMA: Preferred reporting items for systematic reviews and meta-analyses. HRQoL: Health-related quality of life. 
PEDE: Pediatric Economic Database Evaluation 
